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ABSTRACT
Schistosomiasis is a neglected tropical disease (NTD) that infects 206 million
individuals worldwide. This disease is caused by dioecious trematodes of the genus
Schistosoma, and its pathology is associated with the large number of eggs that are released
by the female. Entrapped eggs lead to host immune and inflammatory responses resulting in
disease progression. Chemotherapy provides the main means of control and praziquantel
(PZQ) is the only widely available drug that is used in all mass drug administration (MDA)
programs. As the number of individuals receiving PZQ continues to grow, the development
of PZQ resistance is a concern and increases as the drug pressure placed on the parasites
increases. We employed Next Generation Sequencing (NGS) to provide transcriptomic data
related to four areas of attention: 1) What is the effect of PZQ on the murine host- S. mansoni
interaction, and how does PZQ effect S. mansoni in vivo?, 2) What is the effect at the
molecular level of PZQ on male S. mansoni in vivo?, 3) What is the respective contribution
of R- and S- enantiomers to the S. mansoni transcriptomic response?, and 4) What is the
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molecular basis for reduced PZQ susceptibility in lab strains of S. mansoni exposed to
increasing sub-lethal doses of the drug?
We found that the murine hepatic response to infection follows a T helper 1 (Th1)
response followed by a T helper 2 (Th2) response upon the increase in egg burden that, in
turn, leads to significant granuloma formation and fibrosis. While infected mice treated with
PZQ have a significantly reduced egg burden and granuloma formation, the immune
response remains relatively similar. Additionally quantitative real-time PCR allowed in vivo
examination of ATP-binding cassette (ABC) transporters in juvenile and adult S. mansoni.
Results show juvenile schistosomes had induced activity of multiple members of this gene
family and provides support that these transporters may provide juveniles natural resistance
to PZQ.
The examination of the effects of the enantiomers of PZQ on male S. mansoni
resulted in more differentially expressed transcripts in the R-PZQ treated parasites then SPZQ treated compared to control, with a total of 101 up- and down-regulated transcripts in RPZQ, and 22 in the S-PZQ treated group. The enantiomers shared 4 up-regulated transcripts
and 7 down-regulated transcripts, with S-PZQ having one unique up-regulated transcript
(Smp_125510, putative cadherin). The up-regulated transcripts identified for R-PZQ
contained 26 hypothetical or uncharacterized proteins, 3 major egg antigens, and three heat
shock proteins. The R-PZQ enantiomer is the main anti-schistosomal effector, perhaps
explaining the differences in transcripts expressed between the parasites treated with each
enantiomer.
Lastly the examination of reduced PZQ sensitivity in PR1 S. mansoni revealed a shift
in sex ratio to a prominently female population combined with reduced length in female
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parasites compared to the control parasites. Moreover, we found no association between PZQ
insensitivity and specific gene products or pathways perhaps pointing to a single loss of
function gene mutation or epigenetic interactions involving multiple genes.
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INTRODUCTION
Schistosomiasis infects 206 million people in approximately 78 countries; of these
individuals over 90% live in sub-Saharan Africa (Ross et al., 2017), and it is estimated ~800
million people are at risk of exposure to the disease (Steinmann et al., 2006). Infection occurs
during routine exposure (agricultural, domestic, occupational, and recreational) to infected
water, and the transmission dynamics make children especially susceptible to infection and
account for 111 million cases (Bustinduy et al., 2016). In children the disease has been linked
to anemia, stunted growth, and reduced cognitive capacities (Colley et al., 2014). The
treatment for schistosomiasis depends almost exclusively on the drug praziquantel (PZQ),
and all mass drug administration (MDA) programs rely on praziquantel for the long-term
goal of elimination (King, 2017).
Schistosomiasis is considered a Neglected Tropical Disease (NTD) a term used to
describe viral, bacterial, and parasitic diseases that together impacts the lives of more than 1
billion people in 149 countries (WHO, 2015). NTDs mainly affect populations in poverty
stricken developing regions of the world that lack adequate sanitation, including access to
potable water (WHO, 2015). Schistosomiasis is a parasitic disease caused by dioecious
trematodes in the Genus Schistosoma, with three main species contributing to human cases,
Schistosoma mansoni, Schistosoma haematobium, and Schistosoma japonicum. Schistosomes
have a complex lifecycle involving a definitive host, humans in named species, and a
gastropod intermediate host. S. mansoni and S. haematobium infect aquatic freshwater
Biomphalaria spp and Bulinus spp snails respectively, while S. japonicum infect amphibious
freshwater Oncomelania spp snails (Colley et al., 2014). The parasites undergo asexual
reproduction in the intermediate host and are released into fresh water as infective cercariae,
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which penetrate the skin of definitive hosts and mature into sexually mature adults. The adult
parasites pair up and produce eggs in the venules that must be released into the environment.
In order to cross the endothelium and lining of organs (intestines or bladder) the eggs must
orchestrate an intense cellular response to allow for excretion and continuation of the
parasite’s lifecycle (File, 1995). In the case of S. mansoni, an adult female can lay 100-300
eggs per day but one third to half of the eggs released will not reach the external environment
(Cheever et al., 1994; Pearce and MacDonald, 2002); it is these eggs that become trapped in
host tissues and elicit a host immune response leading to serve pathology (Burke et al., 2009;
Pittella, 1997). Granuloma formation serves to contain proteolytic products resulting from
the egg and provide protection for the host (Fallon, 2000). It is known granulomas are a
predecessor of fibrotic tissue formation leading to an increase in portal blood pressure and
portal systemic shunt formation (Cheever et al., 2002; Wilson et al., 2006).
An overarching observation in Schistosoma infections is an initial T-helper1 (Th1)
response that is pro-inflammatory, which then switches to a T-helper2 (Th2) response upon
egg production (de Oliveira Fraga et al., 2010; La Flamme et al., 2001; Vella and Pearce,
1992). Th2 type responses are needed for minimization of host pathology as seen with
studies that showed mice depleted of Th2 type responses mainly interlukin-4 resulted in
higher mortality related to pathology from pro-inflammatory Th1 type responses (La Flamme
et al., 2001; Patton et al., 2002). Additionally egg antigens are thought to prime activated
macrophages resulting in down-regulation of Th1 responses and thus decreasing mortality
associated with inflammation (Anthony et al., 2007; Hams et al., 2013). To date, there have
been multiple studies involving schistosomiasis immunopathogenesis and all have
investigated specific mechanisms or a small number of genes. One of my research aims was
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to present a global view of the murine host hepatic immune and fibrotic responses as a result
of S. mansoni infection and investigate the effects PZQ has on those transcriptomic responses
(Chapter 1).
The treatment and control of schistosomiasis has relied on PZQ for over 40 years
(Andrews, 1985; Caffrey, 2015; Cioli and Pica-Mattoccia, 2003). The exclusive use of PZQ
is based on the efficacy (40mg/kg in humans yields 60-90% cure)(Doenhoff, 1998), safety
(Sousa-Figueiredo et al., 2012), convenience, and price (Hotez et al., 2010). Although PZQ
has been used for many years the mechanism of action (MOA) remains unknown. The PZQ
effects on schistosomes have been previously studied and it has been demonstrated that PZQ
causes calcium ion influx, muscle contraction, and surface modifications in vitro, and it is
thought the disruption of the parasite’s tegument may lead to exposure of surface antigens
and host recognition and clearance by host immune system (Brindley et al., 1989; Doenhoff
et al., 1987; Harnett and Kusel, 1986; Kohn et al., 2001). The drug is synthesized and
administered as a racemic compound containing equal parts R- (levorotatory, L-PZQ) and S(dextrorotatory, D-PZQ) stereoisomers and studies have shown that the anthelmintic activity
of PZQ is associated with R-PZQ, and its side effects, large pill size, and bitter taste being
attributed to S-PZQ (Andrews, 1985; Meister et al., 2014; Olliaro et al., 2014).
S. mansoni has been shown to have sex and stage related variability to PZQ
sensitivity, and earlier research has shown that in vivo fifty percent drug effective dose
(ED50) in the infected mouse model to be 80.9 mg/kg in bi-sex adult infections (49 days post
infection (dpi)) compared to 2456 mg/kg in bi-sex juvenile infections (28 dpi); in addition
female adult unisex infection had an ED50 of 1107 mg/kg compared to 197.7 mg/kg in male
unisex infections (Pica-Mattoccia and Cioli, 2004; Xiao et al., 1985). Juvenile parasites
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natural resistance to PZQ provides an obstacle when it comes to control of schistosomiasis
because repeated doses of PZQ are needed to kill all the parasites in an individual, a protocol
not currently performed in endemic areas under MDA programs.
MDA programs rely on PZQ to control schistosomiasis and the number of individuals
receiving treatment continues to grow raising concern for emergence of PZQ resistance.
There have been reports of PZQ insensitivity/resistance in the field (Ismail et al., 1996;
Melman et al., 2009; Stelma et al., 1995) but the overwhelming theme is there is no evidence
of widespread or enduring PZQ resistance. In addition, PZQ resistance has been
experimentally induced in the lab multiple times (Couto et al., 2011; Fallon and Doenhoff,
1994; Ismail et al., 1994). In both field and lab selected PZQ resistance there has been some
evidence that PZQ resistance comes at a cost, decreased fitness (Coeli et al., 2013; Melman
et al., 2009; William et al., 2001). The lack of sustained evidence for PZQ resistance in the
field may be attributed to reduced fitness or may be explained by the large refugia of
susceptible parasites resulting in a reduced likelihood that PZQ resistance is sustained. A
study examining an endemic area that 10 years earlier reported PZQ resistance (Ismail et al.,
1996) found no evidence for PZQ resistance in this area that had received multiple PZQ
treatments (Botros et al., 2005) and may provide support for fitness reduction as a tradeoff to
resistance.
The mechanisms by which schistosomes acquire PZQ resistance remains unclear
however studies have provided some clues regarding PZQ resistant parasites. Two studies
have pointed to induction of ATP-binding cassette (ABC) transporters, drug and xenobiotics
influx and efflux pumps. Hines-Kay and colleagues found increased levels of two such
transporters in juvenile parasites compared to adults in vitro (Hines-Kay et al., 2012), and
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Kasinathan et al. (Kasinathan et al., 2010) found juvenile parasites express higher levels of a
ABC transporter gene (SmMRP1) compared to control parasites. Lastly, a recent study
identified characteristic proteins in PZQ resistant S. mansoni, including identifying proteins
unique to female PZQ resistant parasites (Pinto Almeida et al., 2018).
The goal of this dissertation was to gain a better understanding of the intimate
relationship that encompasses the disease triangle of schistosomiasis by looking at the effect
of PZQ on the host (murine), and pathogen (S. mansoni) by applying Next Generation
Sequencing (NGS). The three main areas of focus are to investigate the effect of PZQ on the
murine host-S. mansoni interaction and on S. mansoni in vivo (Chapter 1), examine the effect
of R-and S-PZQ on S. mansoni in vitro (Chapter 2), and examine the molecular basis for
PZQ resistance in S. mansoni (Chapter 3). This dissertation contributes to the field of
schistosomiasis by providing new insights into the transcription profiles related to the three
areas of focus. Ultimately the work conducted has enhanced our understanding of the effect
of PZQ on S. mansoni and provided transcriptional data as the basis of analyses and metaanalyses.
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Abstract
Schistosomiasis is a chronic parasitic disease caused by sexually dimorphic blood flukes of
the genus Schistosoma. Praziquantel (PZQ) is the only drug widely available to treat the
disease but does not kill juvenile parasites. Here we report the use of next generation
sequencing to study the transcriptional effect of PZQ on murine hepatic inflammatory,
immune and fibrotic responses to Schistosoma mansoni worms and eggs. An initial T helper
cell 1 (Th1) response is induced against schistosomes in mice treated with drug vehicle (Vh)
around the time egg laying begins, followed by a T helper cell 2 (Th2) response and the
induction of genes whose action leads to granuloma formation and fibrosis. When PZQ is
administered at this time, there is a significant reduction in egg burden yet the hepatic Th1,
Th2 and fibrotic responses are still observed in the absence of granuloma formation
suggesting some degree of gene regulation may be induced by antigens released from the
dying adult worms. Quantitative real-time PCR was used to examine the relative expression
of 16 juvenile and adult S. mansoni genes during infection and their response to Vh and PZQ
treatment in vivo. While the response of stress genes in adult parasites suggests the worms
were alive immediately following exposure to PZQ, they were unable to induce transcription
of any of the 9 genes encoding ATP-binding cassette (ABC) transporters tested. In contrast,
juvenile schistosomes were able to significantly induce the activities of ABCB, C and G
family members, underscoring the possibility that these efflux systems play a major role in
drug resistance.
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Author summary
Schistosomiasis is a disease caused by parasitic worms that significantly impacts the lives of
approximately 260 million people. During infection, female parasites can release thousands
of eggs, a significant number of which become trapped in the liver. Entrapment of eggs
triggers immune and inflammatory responses that in turn causes many of the health problems
associated with the disease. In this study, we analyzed gene expression profiles of livers from
mice infected with the human parasite Schistosoma mansoni over multiple time points,
beginning when the parasites start to lay eggs. In mice treated with a lethal dose of the antischistosomal drug praziquantel, we identified a number of different genes and pathways
central to immune and inflammatory responses that are active even in the absence of egg
deposition. Praziquantel is the only drug available to treat schistosomiasis, however, it
displays bimodal activity in that it is ineffective against juvenile parasites during the early
stages of mammalian infection. We also show that development of drug resistance may be
due to the improved efficacy of the juvenile parasite to actively excrete the drug. These
results provide insights into the effect of praziquantel on the host response to infection as
well as the ability of juvenile parasites to overcome the drug’s lethal effect.
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Introduction
Schistosomiasis is a chronic neglected tropical disease caused by digenetic parasitic
flatworms of the genus Schistosoma. In 2014, 259 million people were treated for the disease
with 91.4 % of those individuals living in Africa where Schistosoma mansoni and S.
haematobium are the major causative agents [1]. Of those infected globally, an estimated 123
million were school-aged children [1]. The human cost of schistosomiasis in 2010 was
calculated at approximately 3 million years lived with disability [2], however, accurate
numbers are difficult to pin down for a number of reasons, not least of which is the
contribution of co-infection with other helminths as well as HIV [3].
The complex life cycle of Schistosoma spp. requires that free-living cercariae released
from infected fresh water snails burrow through human skin and enter the venous circulation
as schistosomulae [4]. Within a week, parasites migrate to the lungs and reach the
hepatoportal circulation approximately 14 days after penetration of the skin. In experimental
mouse disease models, schistosomes do not develop synchronously though most can be
considered as sexually immature juveniles between 14 and 28 days post infection, with
sexual maturation occurring from day 28 onward. In the case of S. mansoni, sexually mature
adult male and female worms reside in the hepatic portal and mesenteric venous systems of
the host with the female releasing increasing numbers of fertilized eggs, of which
approximately half will migrate through the bowel wall to be excreted in the host stool. The
remaining eggs often become trapped in the liver where they trigger host inflammatory
responses. Hepatic fibrosis and granuloma formation caused by the deposition of collagen
and extracellular matrix components around the eggs leads to the occlusion of the hepatic
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portal veins, which in turn causes portal hypertension, enlargement of the spleen, ascites, and
gastrointestinal bleeding [4,5].
Numerous studies have tracked the expression of immune and inflammatory hepatic
genes during infection, inflammation and granuloma formation. In the early stages of
infection, a T-helper cell type 1 response (Th1) against the parasite has been recognized
through increased production of pro-inflammatory cytokines (TNFα, IL1α, IL1β and IL6) as
well as Signal Transducers and Activators of Transcription 1 (STAT1) and IFNγ [5-7], while
elevated Th17 cell numbers have been suggested to mediate bladder pathology during S.
haematobium infection [8]. As parasite egg deposition commences, a contemporaneous Th2
response characterized by a surplus of chemokine expression as well as IL4, IL5, IL10, IL13
and IL33 production also gets underway [5-7, 9]. In addition, production of IL10 by
regulatory T cells (Treg) may help to control pathology along with IL10 independent
naturally occurring CD4+ Foxp3+ regulatory T cells [10, 11]. Chuah and colleagues used
microarrays to study neutrophil mediated changes in gene expression during granuloma
formation in S. japonicum infected mice and found a significant up-regulation of Th1, Th2
and Th17 immune genes, as well as inflammatory genes within the granuloma that are
spatially and temporally separated [12].
While a number of drugs have been used to treat schistosomiasis only one, praziquantel
(PZQ), is widely employed as it is relatively cheap, easy to use, and effective against all
schistosome species that infect humans [13]. Its use in the past 10 years has increased
significantly as the number of patients treated has grown from approximately 12 million in
2006 to 61.6 million in 2014 when 20.7 % of affected individuals received the drug [1]. This
has largely been due to the implementation of mass treatment campaigns with, for example,
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an increase of 52.3 % in those receiving treatment in the African region when comparing
2014 with the previous year [1].
Although PZQ brings relief to those treated, it does not provide a cure as juvenile
schistosomes are relatively resistant to the anthelmintic effects of the drug [14-17]. When
available, administration of PZQ is often limited to a single dose per year and treated
individuals, frequently children, will quickly become reinfected through continued and
unavoidable exposure to the parasite. Additionally, any juvenile parasites that escape
elimination during treatment subsequently mature and begin to release eggs. The frequent
exposure and survival of resistant juveniles to PZQ also gives concern that under this
ineffective pressure, drug resistance could emerge [18].
In the absence of an anti-schistosomal vaccine, one route to improving treatment of
patients is to enhance the efficacy of PZQ by increasing the sensitivity of juvenile parasites
to the drug. This approach requires an understanding of the molecular basis of juvenile
resistance. While it is possible resistance may be driven by a reduction in expression of the
drug target or an increased rate of drug metabolism, we and others have suggested that ATP
Binding Cassette (ABC) multi-drug transporters play an important role [19-23]. These transmembrane proteins work by hydrolyzing ATP and using the energy liberated to move
compounds, including drugs, across membranes. Drug resistance results from the
amplification, over-expression or modification of some members of this transporter family
[24].
In the current study we use next generation sequencing (RNA-Seq) to quantitate the
effect of PZQ on the mouse hepatic transcriptomic response to S. mansoni infection during
the immediate two-week period following the transition of the parasite from sexually
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immature juvenile to mature adult. We observe that PZQ has little effect on immune and
inflammatory gene regulation in the period immediately following drug treatment, but do
note a significant reduction in these responses in the absence of egg deposition two weeks
after treatment commenced. In addition, we investigate the response of juvenile and adult
schistosomes to treatment with PZQ in vivo by quantitative real-time PCR and demonstrate
that juvenile schistosomes may protect themselves from the lethal effects of the drug through
up-regulation of a number of ABC transporter genes.

Materials and Methods
Ethics statement
This study was performed in accordance with the Guide for the Care and Use of
Laboratory Animals of the U.S. National Institutes of Health. Animal use procedures were
reviewed and approved by the University of New Mexico Institutional Animal Care and Use
Committee.

Mice, parasites and experimental procedures
For all infection experiments, eight to ten-week-old female Swiss Webster outbred mice
(Charles River, Kingston, NY) were each infected percutaneously with approximately 150 S.
mansoni Puerto Rican 1 (PR1) cercariae. Treatment with PZQ (Sigma-Aldrich, St Louis,
MO) was administered by gavage at a dose of 250 mg/kg/day in vehicle (Vh) (Cremophor
EL, Sigma-Aldrich) for four consecutive days. Control mice were either infected or left
uninfected and administered an equivalent volume/kg/day of Vh for four consecutive days.
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To determine the effect of PZQ or Vh on the number of parasites present in the livers of
mice during and after treatment, PZQ or Vh was administered to two groups of 15 mice
infected with S. mansoni (PR1) beginning on day 32 post infection (from this point onwards
all data points will be defined by the time post cercarial challenge i.e., days 32, 35, 39 or 46).
After infection, mice were randomly distributed into the treatment or control group and five
mice from each group sacrificed 3 h after the initial treatment on day 32, after the final
treatment on day 35 and 14 days after treatment commenced (day 46). After euthanasia with
sodium pentobarbital, livers were collected, gently shredded and parasites counted (n = 5 per
group).
The number of eggs present in livers of infected mice receiving PZQ or Vh for four
consecutive days starting on day 32 was also assessed. Mice were sacrificed (n = 4 per
group) on days 32 and 35 (3 h after treatment) and on days 39 and 46. Livers were digested at
37°C overnight in 4 % potassium hydroxide and the number of eggs per gram of liver
calculated [25].
To determine changes in expression of hepatic and schistosomal genes during infection
and PZQ treatment, two groups of 16 mice were infected with S. mansoni and treated with
PZQ or Vh for 4 consecutive days beginning on day 32. Mice were sacrificed 3 h after
treatment (n = 4 per group) on days 32, 35 and on days 39 and 46. A third group of 16
uninfected mice were treated with a weight related dose of Vh (S1 Fig). Three of the four
whole livers were randomly selected and placed in RNAlater (ThermoFisher Scientific,
Waltham, MA) for RNA isolation. The remaining liver was placed in 10 % formalin for
histological analysis. Livers from four uninfected Vh treated mice at each time interval were
used as controls to provide gene expression and histological baseline data.
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Isolation of total RNA
Livers were removed from RNAlater, weighed then placed in RNeasy lysis buffer with 1
% 2-mercaptoethanol (Sigma-Aldrich) and homogenized. Total RNA was isolated using an
RNeasy Maxi Kit (Qiagen) and digestion with RNase-free DNase (Qiagen, Redwood City,
CA) according to the manufacturer’s instructions. Total RNA was quantified using a ND1000 spectrophotometer and the quality verified using an Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, CA). RNA was stored at -80° C. Representative bioanalyzer traces from each
treatment group are shown in S2 Fig and a minimal RNA integrity number (RIN) of 6 was
the threshold for sample use in this study.

Next generation sequencing: cDNA library construction, sequencing and data
processing
RNA sequencing (RNA-Seq) was conducted on three separate biological replicates
representing each type of treatment and time-point using the Illumina Next Generation
Sequencing (NGS) platform (Illumina, San Diego, CA) and was performed at the National
Center for Genome Resources (NCGR, Santa Fe, NM). First strand cDNA libraries were
prepared from 500 ng of polyA+ heat-fragmented RNA using Superscript II (Invitrogen,
Carlsbad, CA) and random hexamer primers followed by second strand cDNA synthesis with
Second Strand Master Mix (Illumina). Universal and bar coded TruSeq Adapters were
ligated to cDNA ends and the resulting adapted cDNA libraries were PCR amplified and
further purified. Samples were normalized to a concentration of 10 nM and pooled prior to
sequencing. Sequencing was performed on a HiSeq 2000 instrument (Illumina) to generate
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50 base-pair single-end reads. The raw sequence reads for each sample were checked for
quality control using FastQC (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc) and
mapped to the S. mansoni (annotation: Ensembl release 75) and Mus musculus (assembly:
GRCm38, annotation: Ensembl release 75) genomes using TopHat2 [26]. The resulting
alignment files were analyzed with Cufflinks [27] and HTSeq-Count [28] to generate a
transcriptome assembly for each data set [29]. Differentially expressed genes (DEG) were
identified in PZQ and Vh treated infected transcriptomes after normalization against Vh
treated uninfected transcriptomes using three separate analysis tools: Cuffdiff [30], DESeq
[31] and edgeR [32] with cutoffs for all programs set at an adjusted p ≤0.05 with log2 fold
change either <-1 (down-regulated genes) or >1 (up-regulated genes). DEG lists for each
sample from each program were displayed using a Venn diagram and only genes common in
multiple bioinformatics approaches were retained for further analysis. The online Lumenogix
platform (api.lumenogix.com) was used to perform all bioinformatics analysis [33]. Twodimensional principal component analysis (PCA) to characterize inter-variable relationships
was performed using R package DESeq2. All high-throughput sequence data sets generated
for this study were deposited with Gene Expression Omnibus and can be accessed through
series GSE19432.

Pathway analysis
Final DEG lists from RNA-Seq analysis were analyzed with Ingenuity® Pathway
Analysis (IPA) tool version 6 (Qiagen). The IPA Knowledge Base incorporates in-house
curating and public databases to formulate and update signaling pathways. Overrepresented
pathways are measured as the probability of association between experimental gene sets
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(DEG) compared to a reference gene set for specific processes or pathways. A right-tailed
Fisher’s Exact Test resulting in a p <0.05 indicates a statistically significant non-random
association.

Gene ontology analysis
Protein Annotation Through Evolutionary Relationship (PANTHER) was used to classify
differentially expressed genes with ontology terms to identify biological functions present in
the final DEG lists based on the statistical overrepresentation test [34].

Quantitative real-time PCR
Mouse RNA used for quantitative real-time PCR (qRT-PCR) originated from the
corresponding liver samples used for Illumina sequencing. qRT-PCR was performed on six
mouse genes to validate the expression patterns observed with RNA-Seq analysis. These
genes were chosen for validation based on their differentially expressed profile in the
Illumina data sets, i.e., having > 20 reads per sample and the qRT-PCR primers passing
efficiency tests. One microgram of total RNA was reverse transcribed in a 20 µL reaction
using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) according to the
manufacturer’s instructions. Predesigned PrimeTime® qRT-PCR gene specific assays
(Integrated DNA Technologies; primer sequences are shown in S1 Table) were used for
RNA-Seq validation. qRT-PCR was carried out in 20 µL reactions containing 100 ng cDNA,
0.5 µM primer and SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad
Laboratories) and performed in biological triplicates with technical duplicates using a C1000
96 Touch Thermo Cycler (Bio-Rad Laboratories). PCR cycling conditions for RNA-Seq
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validation were 95°C for 2 min followed by 40 cycles at 95°C for 5 s, 60°C for 30 s and
65°C for 15 s. Relative expression (2-ΔΔCt) was performed using CFX Manager™ Software
v3.1 (Bio-Rad Laboratories) to calculate the fold change relative to the reference Mus
musculus gene glyceraldehyde-3-phosphate dehydrogenase (PrimePCR™ SYBR® Green
Assay: GAPDH, Mouse, Bio-Rad Laboratories). Expression of this gene did not vary
significantly between treatment groups. Correlation between qRT-PCR and RNA-Seq data
was assessed using a Spearman’s Rho correlation, as the data were not normally distributed.
Data analysis and statistical comparisons were performed using GraphPad Prism (GraphPad
Software Inc., La Jolla, CA).

The expression of 16 juvenile and adult S. mansoni genes were analyzed by qRT-PCR.
These represented genes we previously reported to be differentially regulated as a result of
PZQ treatment in vitro [22] or those identified in the recent literature as being affected by
PZQ including ABC multi-drug transporter, calcium regulatory and stress-related family
members.
To investigate the effect of drug treatment on juvenile S. mansoni gene expression in
vivo, groups of infected mice were treated with Vh or PZQ on four consecutive days
beginning on day 25 as described above. Mice were sacrificed 3 h after treatment (n = 4 per
group) on days 25 and 28 and the livers placed in RNAlater for total RNA isolation. For
qRT-PCR analysis, mRNA was reverse transcribed and parasite gene specific cDNA
amplified. Similarly, mouse liver RNA samples used for Illumina sequencing that contained
infecting adult S. mansoni mRNA were reverse transcribed and parasite gene specific cDNA
amplified. The general conditions for S. mansoni qRT-PCR were as described above. S.
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mansoni GAPDH was used as a housekeeping gene to calculate relative fold change as its
expression did not vary significantly between treatment groups (S2 Table). qRT-PCR cycling
conditions for S. mansoni gene expression were 95°C for 10 min followed by 40 cycles at
95°C for 15 s, 60°C for 1 min and 60°C for 20 s. PCR primers for S. mansoni genes (S3
Table) were designed using the Integrated DNA Technologies OligoAnalyzer tool
(www.idtdna.com). Fold change was calculated as described above. One-way analysis of
variance (ANOVA) was performed to calculate statistical significance of normalized gene
expression between treatment groups and where significance was detected the Fisher’s least
significant difference post hoc test for multiple comparisons was used with p <0.05
considered statistically significant.

Results and Discussion

Effect of praziquantel on parasitic infection
The initial research aim was to identify a suitable four-day treatment window when the
majority of infecting S. mansoni would be mature enough to be PZQ sensitive, but young
enough that egg accumulation and resultant tissue damage in the liver would be negligible.
This would allow a comparison of the host hepatic transcriptome giving insights into
development of both the immune and inflammatory response to PZQ treated worms as well
as to the ongoing infection in those treated with Vh. In addition, it was intended initially that
the worm transcriptomic response to both PZQ and mouse immune and inflammatory
reaction to infection might also be acquired.
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For these studies mice were infected with approximately 150 S. mansoni cercariae. This
level of infection will usually result in around 40-60 worms reaching maturity with the host
becoming debilitated on or around days 49 to 56 post infection. Preliminary studies were
conducted that identified the 32nd day after infection as the optimal time-point to begin PZQ
treatment (data not shown). At this stage, infection was still relatively benign as few if any
eggs had been deposited in the host liver with minimal signs of animal distress or hepatic
damage, yet the majority of worms had matured sufficiently to have acquired sensitivity to
the drug. Administering 250 mg/kg PZQ on day 32 resulted in no immediate effect on the
number of live schistosomes retrieved by dissection from the liver 3 h after treatment
compared with Vh treated infected mice (Fig 1A). After four consecutive daily doses totaling
1000 mg/kg there was a small but significant (p <0.05) drop in the number of live worms
retrieved from PZQ treated (22.4 ± 2.8) compared to Vh treated mice (29.1 ± 1.8). This
difference was greater still (p <0.001) when mice were sacrificed 14 days (day 46) after the
initial treatment when limited numbers of S. mansoni were retrieved from the liver of PZQ
(8.3 ± 5.2) compared with Vh (54.3 ± 17.4) treated mice. The hepatic egg burden was
negligible in controls and drug treated mice at days 32 and 35 but had increased significantly
(p <0.05) in Vh compared with PZQ treated mice on days 39 and 46 (Fig 1B). Treatment
with PZQ resulted in little accumulation of eggs in the liver during the course of the
experiment, however, the number of eggs deposited in the liver of Vh treated mice reached
its maximum on day 46 coinciding with a significant (p <0.001) increase in liver weight
compared to PZQ treated mice (Fig 1C).
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Fig 1. The effects of PZQ on infected host liver. (A) Effect of treatment with Vh and PZQ
on the number of parasites present in host livers at days 32, 35 and 46 post infection, n = 5
per treatment group. (B) Number of parasite eggs per gram of liver at days 32, 35, 39 and 46
post infection after treatment with Vh and PZQ (n = 4). (C) Weight of liver at days 32, 35, 39
and 46 post infection after treatment with Vh and PZQ (n = 4). Error bars represent mean
with standard deviation. * p <0.05 and *** p < 0.001.
Transcriptome sequencing, assembly and analysis
To compare changes in the hepatic transcriptome, cDNA libraries were prepared from the
livers of 24 S. mansoni infected mice treated with PZQ or Vh, as well as 12 uninfected mice
treated with a weight related dose of Vh (S1 Fig). After the removal of adaptor sequences
and any ambiguous or low quality reads (Q <20), a total of approximately 920 million 50
base pair single-end reads were obtained (S4 Table). The mean number of reads in each of
the 12 treatment groups (n = 3 per group) varied between 23.48 and 27.78 million. Sequence
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reads were assigned to the Mus musculus genome assembly and 88.2-91.0 % of individual
library reads with means of 88.9-90.3 % for each group were successfully mapped. The
number of aligned reads per sample was more than sufficient for differential expression
analysis with treatment groups each containing three biological replicates [35]. In contrast,
only a mean of between 0.01 % (uninfected liver from Vh treated mice on days 39 and 46)
and 0.13 % (infected liver from Vh treated mice on days 32 and 35) of reads mapped to the S.
mansoni genome. While the former number likely represents transcripts of high homology
between mouse and parasite as no S. mansoni transcripts should be present, the latter was not
sufficiently robust to allow for inferences to be made regarding the expression of S. mansoni
genes during Vh or PZQ treatment.
When the transcriptomes of the 36 individual mouse livers were compared globally, they
segregated into three distinct clusters with the 12 uninfected Vh samples grouped together
(Fig 2A). Of the infected individuals, the day 32, 35, 39 and 46 transcriptomes from PZQ
treated mice grouped together with the day 32, 35 and 39 transcriptomes from Vh treated
mice with a high degree of sub-clustering generally coincident with the time and type of
treatment. The six day 39 and 46 PZQ treated mice formed a separate sub-cluster indicating
their transcriptomes were distinct from the others within this larger subset. The three day 46
Vh samples formed a distinct third cluster and were more similar to each other than any other
samples, likely reflecting an expanded gene response to increasing egg deposition in these
mice and the ensuing hepatic damage. All three biological replicates associated with each
individual treatment and time grouped closely together, suggesting consistency between
samples and none were omitted from further analyses. PCA was used to further characterize
the relationship between the treatment groups (S3 Fig) and confirmed the internal structure of
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the dendrogram (Fig 2A) and that conditions for the day 46 Vh samples accounted for most
of the variation.

Fig 2. Hierarchical clustering of gene expression between different treatment groups
and differentially expressed genes. (A) Dendrogram showing global similarities between
hepatic transcriptomic replicates (n = 3) of uninfected Vh treated (ui_Vh), infected Vh
treated (Sm_Vh) and infected PZQ treated (Sm_PZQ) mice at days 32, 35, 39 and 46 post
infection. (B) The total number of up- and down-regulated hepatic genes in Vh and PZQ
treated mice compared to uninfected Vh treated control samples at days 32, 35, 39 and 46
post infection. (C) The total number of up- and down-regulated immune genes identified by
GO analysis in Vh and PZQ treated mice compared with uninfected Vh treated control
samples at days 32, 35, 39 and 46 post infection.
As it has already been established that PZQ has no significant effect on the uninfected
mouse liver transcriptome beyond 3 weeks post drug delivery [36] the transcriptomes of the
two infected treatment groups at each time point were normalized against the corresponding
uninfected Vh treated samples and differentially regulated genes were then identified. While
there is no discernible difference in the numbers of differentially regulated genes between the
treatment groups at days 32, 35 and 39, day 46 revealed a substantial increase in the number
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of both up- and down-regulated genes in Vh compared with PZQ treated mice (Fig 2B and
S5 Table). Gene Ontology (GO) analysis revealed that while the number of differentially
regulated genes increased with each time point regardless of treatment, the proportion of each
biological process did not alter significantly (S4 Fig). The identity of all differentiated genes
at each time point and treatment as well as their fold change is shown in S6 Table. The
number of up-regulated genes characterized as ‘immune response related’ by GO analysis
increased over the first three time points irrespective of treatment while the number of downregulated genes was consistent (Fig 2C and S5 Table). At day 46, however, the number of
up-regulated genes in the PZQ samples decreased in comparison to day 39. In contrast, the
number of up- and down-regulated immune genes in the Vh samples increased. These results
suggest that when viewed globally, PZQ treatment has little impact on the host’s immune
response to infection until after day 39 when egg accumulation became more pronounced in
Vh treated animals.

Expression analysis of immune and fibrotic transcripts
To identify the response of individual genes across treatment and time in greater detail,
heat maps were constructed for differentially regulated immune/inflammatory and fibrotic
genes (Fig 3). Of the classic inflammatory cytokines, IL1β was up-regulated at days 32
through 46 in Vh samples but was only induced at days 32 and 35 with PZQ treatment. IL6
was only found to be up-regulated in day 46 Vh samples and TNFα was up-regulated at days
32 through 46 with a peak of activity at day 39 in Vh samples, while treatment with PZQ
resulted in peak at day 39 but this abruptly disappeared at day 46. (Fig 3A).
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Fig 3. Temporal expression of mouse hepatic genes during infection with S. mansoni.
Heat maps of (A) immune and (B) fibrotic gene markers depicting differentially expressed
genes in infected Vh and PZQ treated mice relative to uninfected mice. Gray map sections
represent genes not expressed at that time point or in that treatment group. Regions of blue
and red indicate, relative to uninfected Vh treated controls, increased and decreased gene
expression respectively. The color scale indicates log2 fold change (FC) and the profile of
each group is the average of three biological replicates. Gene names associated with the
figure differ slightly from those used in the text. Relevant differences include: Ccl (rather
than CCL as it appears in the main body of text), Cxc (CXC), Cxcl (CXCL), Il1b (IL1β),
Tnfa (TNFα), Tgfb (TGFβ), Ifng (IFNγ), Cd (CD) and Timp (TIMP).
Previous studies of the immune response to chronic schistosome infection have indicated
that a Th1 response against migrating schistosomulae as well as maturing and mature
schistosomes during the first 28-42 days is followed by a Th2 response driven by egg
deposition and antigen release from the maturing miracidium contained therein [reviewed by
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5]. In this study, Th1 related transcripts, including STAT1, STAT4 and Tbet, generally
increased their expression from day 32 onwards compared to uninfected controls after Vh
treatment (S5A Fig). Of the classical Th1 markers, only IFNγ was increased significantly and
only at days 39 and 46 (Fig 3A and S5A Fig). In contrast, PZQ treatment led to an increase in
expression of all four Th1 markers at days 35 and 39 though again only IFNγ changed
significantly and at both time points with all falling back to initial expression levels at day 46
(Fig 3A and S5B Fig). Th2 related cytokine and chemokines IL4, CCL12 and CCL22 were
elevated most significantly at day 46 in Vh samples but their activities peaked earlier after
PZQ treatment (Fig 3A and S5C, D Figs). TGFβ, a negative immune regulator, was only
elevated in Vh samples and only at day 46 (Fig 3A).
Burke and colleagues examined the temporal expression of immune (and fibrotic) genes
in S. japonicum infected mice [7]. These animals were more lightly infected than reported
here and gene expression profiles were assessed using microarrays on days 28, 42 and 49
post infection. While granulomas formed as a result of S. japonicum infection have been
described as more severe and neutrophilic than those associated with S. mansoni [37], which
are more eosinophilic [38], we observed many of the same transcriptional patterns during the
initiation and establishment of immune responses. Burke and colleagues noted the early onset
of Th1 associated gene expression (i.e. IFNγ, STAT1 as well as CXCL9) peaked at days 2842 with increases in expression of Th2 chemokines (i.e., CCL7 and CCL24) peaking at day
42; a similar pattern of expression was observed for these genes in this study (Fig 3A).
Indeed, a number of CC and CXC chemokine transcripts were observed in both studies to be
elevated at most time points sampled. For example, the early and sustained elevation of T
cell attractants CCL8 and CXCL9 and 10 in both treatment groups as well as the concomitant
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induction of CD4 agrees with observations in S. japonicum [7] and supports the notion that
Th recruitment begins independently of egg deposition. Induction of the B cell cytokine
CXCL13 was also early and sustained, but no change in the B cell marker CD19 was
observed, suggesting no significant recruitment of B cells into the liver as a result of worm
infection or egg deposition.
Although this approach gives insight into the differential expression of key individual
genes, it does not provide a global overview of the effect of infection, treatment and time on
T cell gene networks controlling maturation and differentiation. We used Ingenuity Pathway
Analysis to visualize this complexity and two pathways that best encapsulate this data,
representing T cell maturation/differentiation and fibrosis, are discussed. Vh treatment results
in T cell maturation pathway activity that was likely initiated before day 32 and increased
progressively until day 46 (Fig 4A-D). While a number of key genes involved in Th1
differentiation are progressively up-regulated between days 32 and 46, gene regulation
leading to Th2 differentiation is only apparent at days 39 and 46. Administration of PZQ did
not result in any maturation or differentiation gene activity at day 32, but after completion of
treatment, multiple genes in both the maturation and Th1 and Th2 differentiation pathways
were substantially up-regulated at day 35 and peaking at day 39 (Fig 5A-D). At day 46,
however, the breadth and intensity of these responses declined precipitously.
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Fig 4. Canonical pathway analysis of T helper cell maturation and differentiation in
vehicle treated infected mice. Signaling events in the T cell maturation and differentiation
pathway at (A) 32, (B) 35, (C) 39 and (D) 46 days in infected Vh treated (Sm_Vh) mice.
Increasing expression in infected mice relative to uninfected mice is indicated by deeper blue
shading. None of the genes indicated were down-regulated. Non-expression and nondifferential expression is indicated by a lack of shading.
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Fig 5. Canonical pathway analysis of T helper cell maturation and differentiation in
PZQ treated infected mice. Signaling events in the T cell maturation and differentiation
pathway at (A) 32, (B) 35, (C) 39 and (D) 46 days in infected PZQ (Sm_PZQ) treated mice.
Increasing expression in infected mice relative to uninfected mice is indicated by deeper blue
shading. None of the genes indicated were down-regulated. Non-expression and nondifferential expression is indicated by a lack of shading.
Burke and colleagues noted the early and sustained up-regulation of the eosinophil
chemo-attractants CCL11 and CCL24 [7] and we also observed this pattern in both treatment
groups. It is noteworthy that in the absence of PZQ treatment, CCL11 and CCL24 expression
was especially pronounced on day 46, whereas in the presence of the drug, expression of
both cytokines peaked earlier (Fig 3A). As noted above, eosinophils have a significant
presence in S. mansoni induced granulomas [38] and our data confirms they play a role in
both the initial anthelmintic response as well as establishment of fibrosis. As discussed
above, treatment with Vh resulted in a significant accumulation of parasite eggs in the livers
of infected animals at day 46. Egg accumulation in turn led to development of granulomas
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with significant fibrotic pathology (comparing S6A and C Fig). For hepatic fibrotic markers
there was again substantial differential regulation of individual genes in day 46 Vh samples
(Fig 3B). Many of this subset were members of the collagen gene family including Col1a1
and Col3a1 that encode type I and III collagens respectively. Histological examination of Vh
day 46 liver sections using Picrosirius Red highlighted the deposition of type I and type III
collagen in the surrounding matrix of the granulomas (comparing S6B and D Fig). Other
genes with peak expression coinciding with the fibrotic response in Vh treated animals
included those encoding matrix metalloproteinases (Mmp) 2, 9 and 13 as well as tissue
inhibitors of matrix metalloproteinases (TIMP) 1 but not TIMP 2. These transcripts have
previously been shown to be abundant in S. mansoni and S. japonicum induced fibrosis [6,
39, 40]. A number of genes including Col1a1, Col3a1, Mmp2, 9 and 13 as well as TIMP1
were induced after treatment with PZQ and in the absence of egg deposition or gross fibrosis
suggesting that their expression is also driven by the breakdown of S. mansoni after drug
treatment.
Pathway analysis was employed to provide a global overview of the differential
expression of genes previously identified as being involved in early signaling in hepatic
stellate cells, the major cell type involved in liver fibrosis [41]. Thirty-two days after
infection and three hours after treatment with PZQ or Vh, there was no substantial
differential expression of genes involved in fibrotic pathways (Figs 6A and 7A). Thereafter,
treatment with Vh was associated with a gradual increase in differential expression of
numerous genes across fibrotic networks (Fig 6B-D). In contrast, treatment with PZQ led to
an earlier more pronounced increase in fibrotic markers at day 35 on cessation of treatment
and this level of activity was maintained until day 46 (Fig 7B-D). Examination of these
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pathways at 46 days post infection revealed a 10-fold expansion in the number of genes
across multiple pathways that are differentially regulated irrespective of treatment. A
comparative analysis of different treatments at this time point revealed that Vh treatment led
to a greater diversity and a more pronounced expression of genes across multiple fibrotic
signaling pathways. These observations suggest that treatment with PZQ coincident with
female parasite sexual maturation and egg release dampens but does not eliminate the
occurrence of hepatic fibrotic events.
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Fig 6. Canonical pathway analysis of hepatic fibrosis and stellate cell activation in
vehicle treated infected mice. Signaling events in the fibrotic and stellate cell activation
pathway at (A) 32, (B) 35, (C) 39 and (D) 46 days post infection in infected Vh treated
(Sm_Vh) mice. Increasing expression in infected mice relative to uninfected mice is
indicated by deeper blue shading. Decreased expression is shown in dark red. Nonexpression and non-differential expression is indicated by a lack of shading.

35

Fig 7. Canonical pathway analysis of hepatic fibrosis and stellate cell activation in PZQ
treated infected mice. Signaling events in the fibrotic and stellate cell activation pathway at
(A) 32, (B) 35, (C) 39 and (D) 46 days post infection in infected PZQ (Sm_PZQ) treated
mice. Increasing expression in infected mice relative to uninfected mice is indicated by
deeper blue shading. Decreased expression is shown in dark red. Non-expression and nondifferential expression is indicated by a lack of shading.
Figures 8A and B summarizes Th1, Th2 and fibrotic gene responses in relation to worm
presence and/or elimination and egg burden during and after Vh or PZQ treatment. As
anticipated, markers of Th1 and Th2 immune function and hepatic fibrosis rise with time in
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response to increasing hepatic egg burden and perhaps continued parasite presence (Fig 8A).
With PZQ treatment, expression of T cell networks peaks earlier as drug treatment eliminates
the majority of parasite burden (Fig 8B). Surprisingly, some fibrotic markers also rise in the
absence of egg burden, perhaps in response to mechanical breakdown of parasites in the liver
although no visible fibrosis was present.

Fig 8. Model of Th1, Th2 and fibrotic responses during S. mansoni infection and
treatment. A global representation of Th1, Th2 and fibrotic gene responses during S.
mansoni infection at 32, 35, 39 and 46 days post infection in (A) Vehicle and (B) PZQ
treated mice.
Results obtained from NGS analysis were validated by qRT-PCR of six transcripts
(CCL7, Col1a1, Col6a5, IFNγ, IL1β and Krt4) over each time point for samples from both
Vh and PZQ treated animals (S7 Fig). Patterns observed in the qRT-PCR data mirrored those
obtained by NGS and showed a significant correlation (S8 Fig) between the two across both
treatments (Vh: r = 0.70, p <0.0001; PZQ; r = 0.61, p <0.0001).
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S. mansoni gene expression in vivo
It had been our intention originally to investigate changes in the S. mansoni transcriptome
using the NGS data generated from infected mouse livers. As outlined above and in S4
Table, too few reads were generated to provide a robust data set and we decided to use the S.
mansoni RNA contained within the hepatic samples as template for qRT-PCR analysis of
individual genes of interest, especially those encoding ABC transporters. In a review of the
ABC transporter family in S. mansoni and S. japonicum, Greenberg reported the presence of
21 and 19 family members in each species respectively [42]. He also matched existing
transcripts in the schistosome and NCBI gene and transcript databases with their human
homologs and we have relied on an expansion of that nomenclature to identify the transcripts
quantified to avoid confusion (S3 Table).
While we and others have examined the effect of PZQ on a limited number of ABC
transporters in S. mansoni treated ex vivo, this, as far as we are aware, is the first study to
examine a suite of transporters during drug treatment in vivo. As there is also the potential
that differences in ABC transporter expression may underpin juvenile resistance to PZQ, we
extended our experiments to parasite RNA extracted from livers derived from mice treated
with PZQ and Vh on days 25-28 of infection (Fig 9A). Fig 9B-J shows the differential
expression of nine transporters in juvenile and adult S. mansoni 3 h after the first and fourth
doses of PZQ or Vh. After four consecutive days of PZQ treatment there was a significant
increase in expression of ABCB1-1, B8, C1-1, C1-2, G1 and G2 transcripts in juvenile
schistosomes. No ABC transporter gene showed a reduction in the level of transcription. In
contrast, no ABC transporter gene showed an increase in transcription in adult worms
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exposed to PZQ for 4 consecutive days while ABCB1-3 showed a significant fall. ABCB1-3
and C1-1 showed a significantly higher level of activity in adult compared to juvenile worms
on the first day of treatment with no juvenile genes showing greater activity. In contrast,
when comparing gene expression between juvenile and adult worms on the fourth day of
treatment, genes encoding ABCB1-1, B8, C1-1, C1-2 and G2 all show significantly greater
levels of activity in juveniles with no gene activity significantly greater in adult than juvenile
worms. Essentially, our data indicates that treatment with a ‘lethal’ dose of PZQ over a 4 day
period leads to a significant increase in transcription associated with several ABC transporter
genes belonging to the ABCB, C and G families in juvenile but not adult parasites. These
families are especially noteworthy as some members (ABCB1, C1 and G2) are strongly
associated with the transport of xenobiotics and multi-drug resistance in cancer treatment
[43]. Our data is not in complete agreement with several published studies that have
investigated the response of individual S. mansoni transporters to PZQ. Schistosome
ABCB1-1 transporter (also named SMDR2) and ABCC1-1 (also named SmMRP1) transcript
and protein levels have been shown to be transiently increased in adult schistosomes
following exposure to a sub-lethal dose of PZQ in vitro [19, 20] while the drug has also been
found to be a substrate of ABCB1-1 when this transporter is expressed in CHO cells [21].
Kasinathan and colleagues also demonstrated that S. mansoni ABCB1-1 and C1-1 were
expressed at higher levels in juveniles compared with adult worms and that adult males, but
not females show a significant increase in the level of ABCC1-1 on exposure to a sub-lethal
dose of PZQ [20]. They suggested this data was ‘…consistent with the hypothesis that
increases in levels of schistosome multidrug transporters may be involved in development or
maintenance or reduced susceptibility to PZQ’. This hypothesis was further supported by
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additional data reported by Kasinathan and colleagues in which juvenile and adult S. mansoni
ABC transporter activities were inhibited pharmacologically in the presence of sub-lethal
PZQ concentrations ex vivo [23]. With adult worms, these conditions resulted in an
exacerbation of the effects of PZQ including a loss of motility and tegument disruption,
while juveniles became paralyzed when PZQ doses that they would normally prove
refractory to were applied. In contrast, adult worms in which expression of five ABC
transporters including ABCB1-1 and C1-1 were knocked down showed increased
responsiveness to PZQ. This ex vivo data taken together with the in vivo results reported here,
lends further support to the hypothesis that ABC transporter family members play a
significant role in modulating the response of juvenile and adult schistosomes to PZQ and
underpin juvenile resistance.
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Fig 9. Quantitative real-time PCR analysis of S. mansoni gene expression. Results are
normalized to S. mansoni GAPDH and fold change in gene expression in PZQ treated
schistosomes is shown relative to Vh treated groups. (A) Schematic diagram explaining the
source of S. mansoni RNA for qRT-PCR analysis. (DPI = days post infection). B-Q. Gene
expression in juvenile schistosomes at days 25 and 28 is shown with shaded bars and adults
at days 32 and 35 are shown hatched. (B-D) and (F-H) show the response of full ABC drug
transporters while (E), and (I, J) are half transporters each with homology to a member of the
human B, C and G families. (K-O) show the response of stress genes HSP70, ferritin and
thioredoxin peroxidase (TPX-1, 2 & 3), (P) the response of calmodulin and (Q) response of
voltage-gated Ca2+ channel β subunit respectively. Statistical differences in fold change
between adult and juvenile S. mansoni were assessed using one-way ANOVA followed by
Fisher’s least significant difference post hoc test for multiple comparisons. Error bars
represent +1 standard error of the mean. * p <0.05, ** p <0.01, *** p <0.001.
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In addition to nine ABC transporters, the expression of seven other S. mansoni genes was
examined. Three of these (HSP70, ferritin and thioredoxin peroxidase 1) were selected (Fig
9K-M) as we observed previously that exposure of S. mansoni to PZQ results in induction of
these stress response genes [17, 22]. This observation was broadly repeated in this study,
with all 3 genes being induced significantly in juveniles with ferritin and thioredoxin
peroxidase 1 being induced significantly in adult after four days of treatment suggesting that
both juveniles and adults were still alive at this time. The expression of two other potential S.
mansoni thioredoxin peroxidase homologs (TPX-2 and TPX-3) were also quantified but only
juvenile TPX-2 was found to be differentially expressed after treatment (Fig 9N, O). Finally,
as schistosomes exposed to PZQ have been demonstrated to undergo a Ca2+ - dependent
contraction that appears to be mediated by a voltage gated Ca2+ channel [44], we also
measured expression of a schistosomal calmodulin and voltage gated Ca2+ channel β subunit
transcripts. Binding of Ca2+ is essential for the activation of calmodulin which functions as a
regulator of many different proteins and pathways. Calmodulin and Ca2+ channel β subunit
transcript expression was induced significantly in juveniles after 4 days of treatment (Fig 9P,
Q), however, neither were differentially regulated in adults.
In conclusion, the analysis of livers from mice infected with S. mansoni and treated with
PZQ or its Vh enabled a comprehensive study of the effect of the drug on anthelmintic
transcriptomic responses in the presence and absence of developing granulomas. While the
immune and fibrotic responses in the absence of the drug are significant leading to a severe
pathology that will, in time, prove fatal for the animals, many of the same genes and gene
networks are active in PZQ treated mice. Furthermore, we have demonstrated that several
ABC transporters, especially members of the ABCB, C and G families, are transcriptionally
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enriched in juvenile compared to adult worms after exposure to PZQ. This lends further
support to the hypothesis that differential expression of these transporters underpins the
resistance of juveniles to the drug.
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Supporting information

S1 Fig. Schematic diagram of mouse treatments to generate RNA-Seq data. Three
distinct groups of 16 mice contributed to the RNa-Seq experiment. These included (A)
uninfected mice treated with PZQ vehicle (Cremaphor EL) on days 32-35 post infection with
4 mice each being sacrificed on days 32, 35, 39 and 46 post infection; (B) S. mansoni
infected mice treated with PZQ vehicle (Cremaphor EL) on days 32-35 post infection with 4
mice each being sacrificed on days 32, 35, 39 and 46 post infection and (C) S. mansoni
infected mice treated with PZQ on days 32-35 post infection with 4 mice each being
sacrificed on days 32, 35, 39 and 46 post infection.
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S2 Fig. Representative Bioanalyzer traces of total RNA from murine livers with the
corresponding RNA integrity number (RIN) values from (A) an uninfected vehicle treated,
mouse; (B) a S. mansoni infected vehicle treated mouse and (C) a S. mansoni infected PZQ
treated mouse.

S3 Fig. Two dimensional principal component analysis (PCA). Visualization of the
clustering or scattering of hepatic transcriptome replicates.

49

S4 Fig. Biological process GO terms associated with differentially regulated genes
during S. mansoni infection. Pie charts of the enriched biological processes for genes
significantly up- and down-regulated at days 32, 35, 39 and 46 in infected PZQ and Vh
treated mice. Data were generated using gene ontology (GO) analysis with a Bonferroniadjusted p value ≤0.05.
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S5 Fig. Change in expression of Th1 and Th2 markers as a result of Vh or PZQ
treatment. (A) and (B) show the change in IFNγ, STAT1, STAT4 and TBET expression
during and after treatment with Vh (Sm_Vh) and PZQ (Sm_PZQ) respectively. (C) and (D)
show the change in expression of IL4, IL5, GATA3, CCL12, CCL17 and CCL22 expression
during and after treatment with Vh (Sm_Vh) and PZQ (Sm_PZQ) respectively.

51

S6 Fig. Granuloma formation in the murine liver during S. mansoni infection.
Picrosirius staining (PolySciences Inc., Washington, PA) was performed according to the
manufacturer’s protocol to determine hepatic fibrosis progression. (A) Bright red stain
around the two schistosome eggs in the center field indicates picrosirius dye binding to
collagen fibrils within the granuloma. The section was taken from the liver of an infected
mouse treated with Vh 45 days after infection. (B) The same field of view shown in (A) but
under polarizing light. Yellow-orange birefringence indicates type I collagen fibers while
green birefringence indicates type III. (C) and (D). Section from PZQ treated mouse liver 45
days after S. mansoni infection. No granuloma or collagen fibrils were evident. Slides were
visualized on a Zeiss Axio Scope.A1 using a 20x objective and images were acquired with a
Nikon D5200 Camera fitted with a MM-SLR Adapter. Scale bar = 130 µm.
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S7 Fig. Validation of RNA-Seq gene expression data by quantitative real-time PCR
(qRT-PCR). Log2 changes in expression of genes encoding chemokine Ccl7, collagen type I
pro-α chain (col1a1), collagen type VI α5 chain (Col6a5), interferon γ (IFNγ) interleukin 1β
(IL1β) and keratin 4 (Krt4) in Vh and PZQ treated infected mice at days 32, 35, 39 and 46
post infection. The gene expression profile at each point is the average of three biological
replicates. For both RNA-Seq and qRT-PCR data, regions of red and green indicate gene
expression has increased and decreased respectively.
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S8 Fig. Correlation between NGS and quantitative real-time PCR (qRT-PCR).
Relationship between NGS and qRT-PCR data for six genes over each time point and for
both treatments was established using Spearman’s Rho correlation.

S1 Table. Primers used in Mus musculus quantitative real-time PCR reactions. GAPDH
(ENSMUSG00000057666) primer set is part of the PrimePCR™ Probe Assay (BIORAD
qMmuCED0027497).
S1 Table. Primers used in Mus musculus quantitative real-time PCR reactions.
Ensemble Gene ID

Gene
Symbol

Forward Primer

Reverse Primer

ENSMUSG00000035373

Ccl7

TTTGTTTCTTGACATAGCAGCAT

TCTCACTCTCTTTCTCCAACCA

ENSMUSG00000001506

Col1α1

GAAACCTCTCTCGCCTCTTG

TGGTGAAGCAGGCAAGC

ENSMUSG00000091345

Col6α5

TCCACGATTTCCACTTGATCC

GCCGTCCTAGCTCCAAAG

ENSMUSG00000055170

IFNγ

CTCTTCTCATGGCTGTTTCT

TTCTTCCACATCTATGCCACTT

ENSMUSG00000027398

IL1β

CCACCTCAATGGACAGAATATCA

CCCAAGGCCACAGGTATTT

ENSMUSG00000059668

Krt4

CTCTGCATCAGCCACAGAT3

GATAGCCTGAAGACCACCAAG
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S2 Table. Real time PCR cycle threshold (Cq) raw data for S. mansoni reference gene
GAPDH.
S2 Table. Real-time PCR cycle threshold (Cq) raw data for S. mansoni reference gene GAPDH.
Well

Fluor

Target

A01
A03
A05
A06
A07
A08
A10
A11
B02
B03
B05
B06
B08
B09
B11
B12
C01
C03
C05
C06
C07
C08
C11
C12
D02
D03
D05
D06
D07
D09
D11
D12
E01
E03
E05
E06
E07
E09
E11
E12
F01
F03
F04
F06
F07
F08
F10
F12

SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR

GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5
GAPDH5

Content Sample
Unkn-01
Unkn-01
Unkn-02
Unkn-02
Unkn-03
Unkn-03
Unkn-04
Unkn-04
Unkn-05
Unkn-05
Unkn-06
Unkn-06
Unkn-07
Unkn-07
Unkn-08
Unkn-08
Unkn-09
Unkn-09
Unkn-10
Unkn-10
Unkn-11
Unkn-11
Unkn-12
Unkn-12
Unkn-13
Unkn-13
Unkn-14
Unkn-14
Unkn-15
Unkn-15
Unkn-16
Unkn-16
Unkn-17
Unkn-17
Unkn-18
Unkn-18
Unkn-19
Unkn-19
Unkn-20
Unkn-20
Unkn-21
Unkn-21
Unkn-22
Unkn-22
Unkn-23
Unkn-23
Unkn-24
Unkn-24

25V1
25V1
25V2
25V2
25V3
25V3
28V1
28V1
28V2
28V2
28V3
28V3
32V1
32V1
32V2
32V2
32V3
32V3
35V1
35V1
35V2
35V2
35V3
35V3
25P1
25P1
25P2
25P2
25P3
25P3
28P1
28P1
28P2
28P2
28P3
28P3
32P1
32P1
32P2
32P2
32P3
32P3
35P1
35P1
35P2
35P2
35P3
35P3

Biological
Set Name

Cq

Sm_Vh_25
Sm_Vh_25
Sm_Vh_25
Sm_Vh_25
Sm_Vh_25
Sm_Vh_25
Sm_Vh_28
Sm_Vh_28
Sm_Vh_28
Sm_Vh_28
Sm_Vh_28
Sm_Vh_28
Sm_Vh_32
Sm_Vh_32
Sm_Vh_32
Sm_Vh_32
Sm_Vh_32
Sm_Vh_32
Sm_Vh_35
Sm_Vh_35
Sm_Vh_35
Sm_Vh_35
Sm_Vh_35
Sm_Vh_35
Sm_PZQ_25
Sm_PZQ_25
Sm_PZQ_25
Sm_PZQ_25
Sm_PZQ_25
Sm_PZQ_25
Sm_PZQ_28
Sm_PZQ_28
Sm_PZQ_28
Sm_PZQ_28
Sm_PZQ_28
Sm_PZQ_28
Sm_PZQ_32
Sm_PZQ_32
Sm_PZQ_32
Sm_PZQ_32
Sm_PZQ_32
Sm_PZQ_32
Sm_PZQ_35
Sm_PZQ_35
Sm_PZQ_35
Sm_PZQ_35
Sm_PZQ_35
Sm_PZQ_35

24.45
24.42
24.01
23.99
23.42
23.43
23.53
23.57
23.11
23.14
23.40
23.39
24.86
24.83
22.96
23.01
23.29
23.24
22.50
22.46
24.13
24.11
23.47
23.46
22.91
22.97
24.32
24.36
23.88
23.94
24.38
24.39
24.48
24.49
23.73
23.75
22.71
22.70
25.01
24.97
24.15
24.10
23.79
23.78
23.04
22.99
23.89
23.94

Cq
Cq
Technical Technical
Mean
Std. Dev
24.43
0.02
24.43
0.02
24.00
0.01
24.00
0.01
23.42
0.00
23.42
0.00
23.55
0.03
23.55
0.03
23.13
0.02
23.13
0.02
23.40
0.00
23.40
0.00
24.84
0.02
24.84
0.02
22.98
0.04
22.98
0.04
23.26
0.04
23.26
0.04
22.48
0.03
22.48
0.03
24.12
0.01
24.12
0.01
23.47
0.01
23.47
0.01
22.94
0.04
22.94
0.04
24.34
0.03
24.34
0.03
23.91
0.05
23.91
0.05
24.39
0.01
24.39
0.01
24.48
0.00
24.48
0.00
23.74
0.02
23.74
0.02
22.70
0.01
22.70
0.01
24.99
0.03
24.99
0.03
24.12
0.03
24.12
0.03
23.79
0.01
23.79
0.01
23.01
0.03
23.01
0.03
23.91
0.04
23.91
0.04
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Cq
Biological
Mean
23.95
23.95
23.95
23.95
23.95
23.95
23.36
23.36
23.36
23.36
23.36
23.36
23.70
23.70
23.70
23.70
23.70
23.70
23.36
23.36
23.36
23.36
23.36
23.36
23.73
23.73
23.73
23.73
23.73
23.73
24.20
24.20
24.20
24.20
24.20
24.20
23.94
23.94
23.94
23.94
23.94
23.94
23.57
23.57
23.57
23.57
23.57
23.57

Cq
Biological
Std. Dev
0.45
0.45
0.45
0.45
0.45
0.45
0.19
0.19
0.19
0.19
0.19
0.19
0.90
0.90
0.90
0.90
0.90
0.90
0.74
0.74
0.74
0.74
0.74
0.74
0.64
0.64
0.64
0.64
0.64
0.64
0.36
0.36
0.36
0.36
0.36
0.36
1.03
1.03
1.03
1.03
1.03
1.03
0.44
0.44
0.44
0.44
0.44
0.44

S3 Table. Primers used in S. mansoni quantitative real-time PCR reactions.
S3 Table. Primers used in S. mansoni quantitative real-time PCR reactions.
Gene ID

Gene

Forward Primer

Reverse Primer

Smp_055780

ABCB1-1 (SMDR2)

CGGTGCTACTCAGGGTTATTT

TCACCAAGGAAGCAATGACTAA

Smp_170820

ABCB1-2

TTTGGGAGCTGCAATGTTTATC

CCTCCGAGTGTTGTTCCAATA

Smp_089200.1

ABCB1-3

GGTTCAGCTGCGAAATGTATTC

CACAACCAGAAGGTCCAACTA

Smp_063000

ABCB8 (SMDR1)

CTTATTCGGTGCCATTCTGG

TTCGTGAGTCACAACGCATC

Smp_171740

ABCC1-1 (SmMRP1)

GGTCGTACTGGTTCGGGTAA

TGAACGTAACGTGCCAGAG

Smp_129820.1

ABCC1-2 (SmMRP2)

TTATGGCGTGCAATAGAATCTG

AGATTTGCTCCACCTTCACC

Smp_147250

ABCC10

CCTCCCTGGACCTTATACAAAC

CGAAGTAAGGTGAGAGGAACAG

Smp_181150

ABCG1

GTTTAGTCCCTTACCTCGCATC

ATTCACCACAAGCCACTTCC

Smp_126450

ABCG2 (BCRP)

AGACCATTCCCACAACACTATC

CGTCCAGCCAACACATCTAA

Smp_186020.1

Heat Shock Protein 70

ACTTAATCGGACCATACACGG

GCAAACATTCCACGTCTCAAAC

Smp_047660.1

Ferritin 2 (soma)

TGTCAATGGAGAAGGCAGTG

TGTCAATGGAGAAGGCAGTG

Smp_059480.1

Thioredoxin Peroxidase-1

GCTGACCGTAAACAGGAGATT

TTCACCGGACACACTTCAC

Smp_158110.1

Thioredoxin Peroxidase-2

CTTGACGAACAGGAAGGTCAT

GAGAGAGAAGCAACAGGATCAG

Smp_004470.1

Thioredoxin Peroxidase-3

GGTGGTGGATGGCCAATTTA

GTTTCTGATAGTCCGCCAAGAG

Smp_026560

Calmodulin-1

CAGAATCCTACAGAGGCTGAAC

TCGCCCAAGTTAGTCATTACAT

Smp_141660.1

VGCC β Subunit

GGTTGTTTTCGTCGTGCGAA

TCGCTGGTGACGGAATAAAG

Smp_056970.1

SmGAPDH

GTCATTCCAGCACTAAACGG

CCTTCCCTAACCTACATGTCAG

S4 Table. Summary of Illumina read counts for each sequenced sample.
Please see publication Sanchez, M.C., Krasnec, K.V., Parra, A.S., von Cabanlong, C.,
Gobert, G.N., Umylny, B., Cupit, P.M., Cunningham, C., 2017. Effect of praziquantel on the
differential expression of mouse hepatic genes and parasite ATP binding cassette transporter
gene family members during Schistosoma mansoni infection. PLOS Neglected Tropical
Diseases 11, e0005691. https://doi.org/10.1371/journal.pntd.0005691.s014
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S5 Table. Number of differentially regulated genes in Vh and PZQ treated samples.
S5 Table. Number of differentially regulated genes in Vh and PZQ treated
samples.
Immune
Immune
Timepoint
Total genes
Total genes
genes
genes
Treatment
upregulated downregulated
upregulated downregulated
Sm_Vh_32

248

47

45

0

Sm_Vh_35

546

21

91

0

Sm_Vh_39

1191

293

150

6

Sm_Vh_46

2633

1687

205

36

Sm_PZQ_32

147

80

21

0

Sm_PZQ_35

927

149

100

3

Sm_PZQ_39

1304

474

153

10

Sm_PZQ_46

937

387

93

9

S6 Table. Identities of all differentially expressed hepatic genes at each time point and
treatment.
Please see publication Sanchez, M.C., Krasnec, K.V., Parra, A.S., von Cabanlong, C.,
Gobert, G.N., Umylny, B., Cupit, P.M., Cunningham, C., 2017. Effect of praziquantel on the
differential expression of mouse hepatic genes and parasite ATP binding cassette transporter
gene family members during Schistosoma mansoni infection. PLOS Neglected Tropical
Diseases 11, e0005691. https://doi.org/10.1371/journal.pntd.0005691.s014

57

Chapter 2
Initial Analysis: The transcriptomic response of Schistosoma mansoni exposed to R- and
S- praziquantel in vitro.

Melissa C. Sancheza, Lijing Bua, Thomas R. Webbb, Pauline M. Cupitc, Charles
Cunninghama*

a

Dept. of Biology, University of New Mexico, Albuquerque, NM, USA

b
c

SRI International, Menlo Park, CA 94025, USA

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San

Diego, La Jolla, CA, USA

+

These authors contributed equally to this paper.

*

Corresponding author at: Dept. of Biology, Room 216 Castetter Hall, University of New

Mexico, Albuquerque, NM 87131, USA. Tel: +1 505 277 5578; fax: +1 505 277 0304; Email ccunnin@unm.edu

58

Abstract
Schistosomiasis is a highly prevalent neglected tropical disease caused by blood-dwelling
helminths of the genus Schistosoma. Praziquantel (PZQ) is the only drug that is widely
available for the treatment of the disease and is administered as large, bitter tasting tablets
which many patients, especially children, find hard to swallow. The drug is synthesized and
administered in its racemic form combining R- and S- stereoisomers in equal amounts,
however, while the anthelmintic activity of PZQ is associated with the R-enantiomer, its side
effects and bitter taste have been attributed to the S-enantiomer. Previously, we have
published a protocol for the synthesis of highly pure gram amounts of the individual isomers.
In this preliminary analysis we have used these synthetic compounds to investigate the effect
of each isomer on the transcriptome of sexually mature Schistosoma mansoni PR1.
Treatment with R-PZQ resulted in the differential regulation of almost 5-fold more
transcripts than S-PZQ and while there was little overlap in the gene sets we note that many
of the most highly differentially regulated transcripts were affected by both the R- and Sisomers. One concern is that, unlike previous studies with racemic PZQ we saw no evidence
of differential regulation of specific stress response genes such as ferritin or thioredoxin
peroxidase. Thus, we will shortly reexamine our data to make sure that in using relatively
conservative cut-off parameters to judge whether genes are differentially regulated, we have
not missed a more informative gene set.
Keywords: Praziquantel, enantiomers, transcriptome, proteome, Schistosoma, helminth
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1.

Introduction
Schistosomiasis is a water borne parasitic disease that affects more than 200 million

people, mainly in sub-Saharan Africa, with approximately 111 million being school aged
children [1]. While the level of mortality is not as significant as that associated with
HIV/AIDS or malaria [2], it is a disease associated with poverty and poor sanitation,
infection with multiple overlapping parasites and a significant economic and health load for
affected populations with, for example, a calculated global disease burden of up to 56 million
disability adjusted life years lost in 2010 [3].
The causative agents of schistosomiasis are digenetic trematode worms belonging to the
genus Schistosoma with Schistosoma mansoni, S. japonicum and S. haematobium being
responsible for the majority of cases. Unfortunately, there is no vaccine and little prospect of
one becoming available in the near future. Treatment of the disease relies on a single drug,
praziquantel (PZQ), that is cheap, widely available, easy to use and effective against all
schistosome species that infect humans [4]. In 2016, approximately 64 million people were
treated with PZQ [1] leading to a significant drop (from 249 million including 114 million
schoolchildren in 2014) in the number of people with the disease. While this is a success to
be celebrated, there remain concerns that increasing intensity of use may eventually cause
PZQ to be lost to resistance in sexually mature parasites. In fact, one drawback of the PZQ is
its failure to kill sexually immature, juvenile parasites [5,6]. Thus a single treatment, which is
usual in poor, remote communities, often does not effect a complete cure but does reduce the
worm burden of an individual. While the molecular basis of juvenile resistance is unclear we
and others have suggested that sexually immature but not mature schistosomes induce
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transcription of ATP Binding Cassette (ABC) transporter efflux pumps to keep the
intracellular concentration of the drug at sub-lethal levels [7-10].
Currently PZQ is synthesized and employed as a racemic mixture of R- and Sstereoisomers. The anthelmintic activity of the drug is associated with the R- isomer [11,12],
while the inactive S-isomer has been implicated in the drug’s side effects [13] and extremely
bitter taste [14] which, together with its large size [15], often makes it difficult to swallow,
especially for children. We have previously published a protocol for the small-scale synthesis
and separation of both the R- and S-PZQ enantiomers [16]. Each isomer can be produced in
gram amounts with an optical purity of greater than 99.999%. Thus while the S-isomer
contains trace R-isomer contamination, it is present in such low amounts that it is likely,
therapeutically insignificant. We calculated the EC50 of racemic PZQ to be 2.5 µM in in
vitro assays while the R-isomer was 0.5 µM and approximately 160–fold more effective than
the S-isomer [16]. We also noted that like racemic PZQ, R- but not S-PZQ causes worms to
become paralyzed at sub-lethal concentrations, presumably due to the influx of Ca2+ ions that
has been observed on drug exposure [17].
We have previously examined the effect of racemic PZQ on the transcriptome of S.
mansoni in vivo [10] and in vitro [9]. In these studies we were able to observe the differential
regulation of stress response, ABC transporter and Ca2+ regulated genes among many others.
What was unclear was which of these genes were being differentially regulated by the Rand/or S- enantiomer. Having highly pure, gram amounts of each has allowed us to begin to
tease out the relative contribution of each enantiomer to this response and we present our
initial findings in this manuscript.
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2.

Materials and Methods

2.1.

Ethics statement
This study was performed in accordance with the Guide for the Care and Use of

Laboratory Animals of the U.S. National Institutes of Health. The University of New Mexico
and University of California, San Diego Institutional Animal Care and Use Committees
reviewed and approved all animal procedures used in this study.

2.2.

Isolation and treatment of schistosomes in vitro with R- and S-PZQ in vitro
Praziquantel enantiomers (R) – [-] PZQ and (S) – [+] PZQ were synthesized and purified

as described by Sharma et al. [16]. For use in vitro, each enantiomer was dissolved in
dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO) to produce stock concentrations
of 50 µM.
Swiss Webster (SW) outbred mice (Charles River, Kingston, NY) were each infected
with approximately 150 S. mansoni Puerto Rican 1 (PR1) cercariae per mouse. Mice were
euthanized and perfused with RPMI 1640 media (RPMI; Sigma-Aldrich) at 49 days post
infection (dpi). Male parasites were randomly divided into three groups of four biological
replicates (~40 parasites per replicate) and placed in enriched RPMI (RPMI containing 5%
Fetal Bovine Serum (FBS; Sigma-Aldrich) and 1% Penicillin/Streptomycin (Sigma-Aldrich))
overnight at 37 °C and 5% CO2. Next day each group was incubated in 5 mL fresh, enriched
RPMI containing final concentrations of either 1% DMSO (control treatment), 0.5 µM RPZQ in 1% DMSO or 0.5 µM S-PZQ in 1% DMSO. Parasites were incubated for 18 h at 37
°C and 5% CO2 then rinsed three times with RPMI 1640 and placed in RNeasy lysis buffer
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(Qiagen, Redwood City, CA) with 1% 2-mercaptoethanol (Sigma-Aldrich) and stored at -80
°C prior to total RNA extraction.

A

B

C

S1 Fig. Total RNA qualitative and quantitative analysis. Bioanalyzer data showing total
RNA gel image (left) with ladder for reference and electrogram (right) from representative
samples (A) R-PZQ, (B) S-PZQ and (C) Control. [FU] = fluorescent units and [s] = retention
time in seconds.
Total RNA was isolated using an RNeasy Mini Kit (Qiagen) including a digestion with
RNase-free DNase (Qiagen) according to the manufacturer’s instructions. RNA was further
purified and concentrated (Zymo Research, Irvine, CA), and total RNA quantified using a
Qubit Fluorometer (Thermo Fisher Scientific, Waltham, MA) and the quality verified with an
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Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Bioanalyzer traces from each treatment
showed no significant RNA degradation (Supplementary Figure 1; S1 Fig.). RNA was stored
at -80 °C until required.

2.3.

Next generation sequencing: cDNA library construction, sequencing and data
processing
RNA sequencing (RNA-Seq) was conducted on four separate biological replicates

representing each type of treatment using the Illumina Next Generation Sequencing (NGS)
platform (Illumina, San Diego, CA). RNA-Seq libraries were generated using a KAPA
Stranded mRNA-Seq Kit (KAPA Biosystems, Wilmington, MA). Poly-A mRNA was
isolated using oligo dT magnetic beads, fragmented, and first strand cDNA synthesis primed
using random hexamers. Second strand synthesis was performed and 2nd strand marked with
dUTP and dAMP was added to the 3’ end of the double stranded cDNA. Unique bar-coded
adapters (Integrated DNA Technologies, Inc., Skokie, IL) were ligated to the cDNA and the
resulting product amplified by PCR. The resulting libraries were quality controlled using a
Qubit Fluorometric analysis and Bioanalyzer to determine quantity and fragment size.
Libraries were further quantified using KAPA Library Quantification Kit (KAPA
Biosystems) for Illumina platform. All samples passing the quality control were pooled.
Samples were sequenced using an Illumina NextSeq 500 (Illumina) to generate 75 bases
paired-end reads. The raw sequence reads for each sample were checked for quality control
using Trimmomatic v0.36 [18] and mapped to the S. mansoni transcriptome annotated from
assembly GCA_000237925.2 ASM23792v2 (NCBI) using Bowtie2 [19]. Gene expression
levels were estimated with RSEM v1.18.1 [20]. Differentially expressed genes (DEG) were
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identified in R-PZQ and S-PZQ transcriptomes after normalization against control
transcriptomes using three separate analysis tools: DESeq2 v1.18.1 [21], EBSeq v1.18.0 [22]
and EdgeR v3.20.8 [23]. Results were organized using SARTools [24], with cutoffs for all
programs set at an adjusted p ≤0.05 with log-fold change either <-1 (down-regulated genes)
or >1 (up-regulated genes). DEG lists for each sample from each program were displayed
using a Venn diagram and only genes common in at least two bioinformatics approaches
were retained for further analysis. All high-throughput sequence data sets generated for this
study were deposited with NCBI Gene Expression Omnibus and can be accessed through
accession number GSE114506.

2.4.

Gene Ontology analysis
Blast2GO [25] version 5.0.13 was used to classify DEG with ontology terms to identify

biological functions present. A statistical assessment was conducted with the FatiGO package
in Blast2GO to identify statistical over or under represented ontology terms in the final DEG
lists using Fisher’s Exact Test correcting for multiple testing with a FDR ≤ 0.05) [26].

2.5.

RNA-Seq Validation
S. mansoni RNA samples for quantitative real-time PCR (qRT-PCR) originated from the

corresponding samples used for RNA-Seq in order to validate Illumina data set expression
patterns. Genes were chosen based on qRT-PCR primers passing efficiency tests and their
differential expression patterns profile in the RNA-Seq data sets, i.e., being expressed in both
R-PZQ and S-PZQ samples. One microgram total RNA was reverse transcribed in a 20 µL
reaction using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA)
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according to the manufacturer’s instructions. qRT-PCR was performed in biological
triplicates with technical duplicates. S. mansoni gene specific qRT-PCR primers (Table S1)
were designed using the Integrated DNA Technologies OligoAnalyzer tool
(www.idtdna.com).

S1 Table. Primers used in S. mansoni quantitative real-time PCR reactions.
Gene ID

Gene

Forward Primer

Reverse Primer

Smp_056970

SmGAPDH

GTCATTCCAGCACTAAACGG

CCTTCCCTAACCTACATGTCAG

Smp_123260

AN1 type zinc finger
and ubiquitin

ATCCGCGGTTTATCTGGTGC

TGGTCAGTTAATTCAACACCGG

Smp_170340

Collagen alpha 1(IV) GAAGAAGGCTGTTGTGGTGC
chain

Smp_144700

5' AMP activated
protein kinase
subunit gamma

ACAGCACCGTCCATATCACC

GTACACTGGGTGACTGTCGG

Smp_160360

Sodium:chloride
dependent
neurotransmitter

CGAACTGCATTACTTGATGGTGC

TTGAGTTCCTGCATCCGACC

Smp_008070

Thioredoxin

CGACAAACTTGAAGAGACCGC

AGAAGCCCCAACAACATCCC

TTCTCCCACACCATCGATGC

Each 20 µL reaction contained SsoAdvanced Universal SYBR® Green Supermix (BioRad Laboratories), 100 ng cDNA, and 0.5 µM primer and was performed using a C1000 96
Touch Thermo Cycler (Bio-Rad Laboratories). qRT-PCR cycling conditions were as follows;
95°C for 10 min followed by 40 cycles at 95°C for 15 s, 60°C for 1 min and 60°C for 20 s.
Relative expression (2-ΔΔCt) was performed using CFX Manager™ Software v3.1 (Bio-Rad
Laboratories) to calculate the fold change relative to the reference S. mansoni gene
glyceraldehyde-3-phosphate dehydrogenase (SmGAPDH). Expression of this gene did not
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vary significantly between treatment groups (Table S2).

S2 Table. Real-time PCR cycle threshold (Cq) raw data for S. mansoni reference gene GAPDH
Well

Fluor

Target

Content

Sample

Biological
Set
Name

Cq

Cq
Mean

Cq
Std. Dev

A01

SYBR

GAPDH

Unkn-01

C_S1

control

21.65

21.68

0.064

A02

SYBR

GAPDH

Unkn-01

C_S1

control

21.75

21.68

0.064

A03

SYBR

GAPDH

Unkn-02

C_S1

control

21.63

21.68

0.064

A04

SYBR

GAPDH

Unkn-02

C_S2

control

20.45

20.47

0.025

A05

SYBR

GAPDH

Unkn-03

C_S2

control

20.48

20.47

0.025

A06

SYBR

GAPDH

Unkn-03

C_S2

control

20.50

20.47

0.025

A07

SYBR

GAPDH

Unkn-04

R-PZQ_S1

R-PZQ

21.43

21.38

0.044

A08

SYBR

GAPDH

Unkn-04

R-PZQ_S1

R-PZQ

21.36

21.38

0.044

A09

SYBR

GAPDH

Unkn-05

R-PZQ_S1

R-PZQ

21.35

21.38

0.044

A10

SYBR

GAPDH

Unkn-05

R-PZQ_S2

R-PZQ

21.83

21.82

0.060

A11

SYBR

GAPDH

Unkn-06

R-PZQ_S2

R-PZQ

21.76

21.82

0.060

A12

SYBR

GAPDH

Unkn-06

R-PZQ_S2

R-PZQ

21.88

21.82

0.060

B01

SYBR

GAPDH

Unkn-07

R-PZQ_S3

R-PZQ

20.70

20.74

0.053

B02

SYBR

GAPDH

Unkn-07

R-PZQ_S3

R-PZQ

20.72

20.74

0.053

B03

SYBR

GAPDH

Unkn-08

R-PZQ_S3

R-PZQ

20.80

20.74

0.053

B04

SYBR

GAPDH

Unkn-08

R-PZQ_S4

R-PZQ

21.48

21.51

0.066

B05

SYBR

GAPDH

Unkn-09

R-PZQ_S4

R-PZQ

21.47

21.51

0.066

B06

SYBR

GAPDH

Unkn-09

R-PZQ_S4

R-PZQ

21.59

21.51

0.066

B07

SYBR

GAPDH

Unkn-10

S-PZQ_S1

S-PZQ

20.45

20.42

0.046

B08

SYBR

GAPDH

Unkn-10

S-PZQ_S1

S-PZQ

20.45

20.42

0.046

B09

SYBR

GAPDH

Unkn-11

S-PZQ_S1

S-PZQ

20.37

20.42

0.046

B10

SYBR

GAPDH

Unkn-11

S-PZQ_S2

S-PZQ

20.70

20.72

0.017

B11

SYBR

GAPDH

Unkn-12

S-PZQ_S2

S-PZQ

20.73

20.72

0.017

B12

SYBR

GAPDH

Unkn-12

S-PZQ_S2

S-PZQ

20.73

20.72

0.017

C01

SYBR

GAPDH

Unkn-13

S-PZQ_S3

S-PZQ

20.93

20.86

0.064

C02

SYBR

GAPDH

Unkn-13

S-PZQ_S3

S-PZQ

20.81

20.86

0.064

C03

SYBR

GAPDH

Unkn-14

S-PZQ_S3

S-PZQ

20.83

20.86

0.064

C04

SYBR

GAPDH

Unkn-14

S-PZQ_S4

S-PZQ

20.05

20.05

0.045

C05

SYBR

GAPDH

Unkn-15

S-PZQ_S4

S-PZQ

20.09

20.05

0.045

C06

SYBR

GAPDH

Unkn-15

S-PZQ_S4

S-PZQ

20.00

20.05

0.045

The log2-fold change of qRT-PCR was derived on the basis of expression values from
treatment averaged from three samples and expressed as the ratio compared to the control
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group. Correlation between qRT-PCR and RNA-Seq data was assessed using a Spearman’s
Rho correlation, as the data were not normally distributed. Data analysis and statistical
comparisons were performed using GraphPad Prism (GraphPad Software Inc., La Jolla, CA).

3.

Results and Discussion
We have previously demonstrated that, when tested in vitro against sexually mature S.

mansoni PR1, the EC50 of the synthetic R–and S-PZQ available for these experiments was
0.5 µM and 78.1 µM respectively [16]. This difference in efficacy is unsurprising as R-PZQ
was identified at an early stage as having the significantly greater anthelmintic activity
[11,12]. As PZQ is administered to patients and animals as a racemic mixture containing
approximately equal amounts of R- and S-PZQ we decided to identify the transcriptomes
induced by each enantiomer at 0.5 µM to compare their effects relative to each other at a
single dose, (due to cost and enantiomer availability), that is sub-lethal. We acknowledge this
may result in a loss of data associated with S-PZQ exposure at higher concentrations,
however, we felt it would more realistically capture the relative contribution of each
enantiomer to the schistosomal response to the drug when it is administered in vivo.

3.1.

Transcriptome sequencing and analysis
cDNA libraries were prepared from pooled, mixed sex mature schistosomes after

overnight exposure in vitro to 0.5 µM of each enantiomer. On removing adapter sequences
and any ambiguous, low quality reads (Q<20), a total of 512.6 million, 75 base paired-end
reads were obtained (S3 Table).
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S3 Table. Summary of Illumina read counts and mapped reads for each sequenced sample

Sample

Total quality-trimmed
paired reads (Q>20)

Percentage of S. mansoni
mapped reads

C_S1

50,037,818

60.02

C_S2

30,637,990

64.25

C_S3

47,228,652

62.25

C_S4

39,101,959

62.16

R-PZQ_S1

44,144,467

64.03

R-PZQ_S2

40,990,919

61.50

R-PZQ_S3

42,779,709

61.08

R-PZQ_S4

40,770,368

63.98

S-PZQ_S1

44,441,980

66.00

S-PZQ_S2

48,958,544

63.04

S-PZQ_S3

45,114,001

66.41

S-PZQ_S4

38,466,340

65.09

The mean number of reads in the control, R- and S-PZQ groups was 41.8, 42.2 and 44.3
million respectively with a mean of 62.2, 62.7 and 65.1 % paired end reads mapped to the S.
mansoni genome. Each group contained 4 biological replicates and the number of reads
provided enough coverage for differential expression analysis [27].
Principal component analysis of the transcriptomes indicated that one of the control
samples was a significant outlier to the others which clustered tightly with the 4 S-PZQ
samples (S2 Fig). The R-PZQ samples clustered together but separately from the S-PSQ and
control samples. In this initial analysis, all samples were retained for further analyses to
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maintain an n of 4 across all groups, however, prior to publication the data will be reanalyzed
using an n of 3 across all groups after discarding the outlier control sample and one of both
the R- and S- samples to establish if the outlier is causing an under- or over-reporting of
DEGs.

R-PZQ

10

S-PZQ
Control

PC2: 19%

5

0

-5

-10
-10

-5

0

5

10

PC1: 31%

S2 Fig. Principal component analysis. Two-dimensional principal component (PC) was
used to characterize the scattering or clustering of replicates in each treatment groups.
Three programs (DESeq, EBSeq, and EdgeR) were used to identify differential transcript
expression and PZQ treated samples were normalized to controls for each isomer. The
number of DEGs observed using each program is shown in S3 Fig and transcripts that were
identified by at least 2 of the programs were retained for further analyses. The number of
differentially regulated genes associated with R- and S-PZQ treatment was 101 and 22
respectively (S4 Table).

70

A

B

DESeq

DESeq

0

9

0

1

3
42
13

6

0
1

99

EdgeR

3

0

EBSeq

C

45

EdgeR

EBSeq

D
DESeq

DESeq

0

2

6

2

7

3

EdgeR

7

1
5

19

37

1

EBSeq

EdgeR

4

36

EBSeq

S3 Fig. Venn diagrams displaying selection process of differentially expressed genes in
this study. Three programs (DESeq, EBSeq, and EdgeR) were employed to find
differentially expressed genes in R- and S-PZQ treated schistosomes compared to controls.
Only differentially expressed genes that were seen in at least two of these programs were
maintained for the study. Separated differentially expressed genes in this study are shown in
the triangle, (A) R-PZQ up-regulated, (B) S-PZQ up-regulated, (C) R-PZQ down-regulated,
and (D) S-PZQ down-regulated.
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S4 Table. Identities of all differentially expressed genes for R-PZQ
and S-PZQ

Passage

Total genes upregulated

Total genes
down-regulated

R-PZQ

67

34

S-PZQ

5

17

This lower number of DEGs associated with the S-PZQ was perhaps unsurprising given
the relatively weak anthelmintic effect of the compound at the concentration employed. An
additional observation is that though treatment with S-PZQ resulted in the differential
regulation of only 22 genes, 11 of these were shared with R-PZQ suggesting that while SPZQ may not have the anthelmintic specificity, both compounds may share ‘off target’
effects on the transcriptome (Fig. 1).

A

B

R-PZQ
63

4

S-PZQ
1

R-PZQ
27

7

S-PZQ
10

Fig 1. Venn diagrams of differentially expressed genes. Indicated in the Venn diagrams
are the numbers of (A) up-regulated and (B) down-regulated differentially expressed genes
shared or exclusive to each treatment. The diameter of each circle is proportional to the
number of transcripts it represents.
No Gene Ontology analysis of overrepresented GO terms is provided as only between 1-3
genes were selected for any particular Biology Process term rendering a limited analysis.
72

Heat maps were constructed for all differentially regulated genes. Among the 68 upregulated genes, 24 were hypothetical or unnamed (Fig. 2, Table S5). The two genes showing
the greatest level of up-regulation after treatment with R-PZQ, Smp_174240 (log2 = 5.5) and
Smp_041730 (log2 = 4.4) were also the two highest differentially regulated after S-PZQ
treatment (log2 = 4.4 and 4.1 respectively). While Smp_174240 encodes a hypothetical
protein, Smp_041730 encodes a homolog of putative pre-mRNA-splicing factor cwc-21. The
third most induced transcript in the R-PZQ cohort was splicing factor 3b (Smp_141630, log2
= 4.1) and the induction of two putative arginine/serine-rich splicing factors (Smp_036270,
log2 = 1.20 and Smp_032320, log2 = 1.02), two DNA-binding Early Growth Response
proteins (Smp_094930, log2 = 1.54 and Smp_134870, log2 = 1.40), two basic helix-loophelix dimerization regions that characterize dimerizing transcription factors (Smp_132810,
log2 = 3.05 and Smp_067430, log2 = 2.69) as well as cut-like 1 (log2 = 1.27) and Far
Upstream element (FUSE) (Smp_044550, log2 = 1.06) DNA binding proteins confirms that
one general effect of PZQ exposure is increased levels of transcription and transcript
processing.
A second group of genes differentially regulated by R-PZQ were those encoding heat
shock proteins including Smp_049240 (log2 = 2.94), Smp_186020 (log2 = 2.1) and
Smp_049250 (log2 = 1.49). One of these, Smp_186020 which encodes Heat Shock Protein
70 was upregulated in juvenile S. mansoni in the 3 h following treatment with racemic PZQ
in vivo [10]. No other previously identified stress response genes such as ferritin
(Smp_047660) or thioredoxin peroxidase -1 (Smp-059480) that have been shown to be
induced after PZQ treatment were elevated in this study.
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Other induced genes of note included Receptor for activated Protein Kinase C
(Smp_102040, log2 = 3.88), and three major egg antigen transcripts (Smp_049300.1, log2 =
2.98; Smp_049300.2, log2 = 2.51 and Smp_049300.3, log2 = 1.85). Receptor for activated
Protein Kinase C has been associated with PZQ resistance [28], however, its up-regulation in
this non-PZQ selected strain suggests its differential regulation is unrelated to resistance.
Major egg antigen (Smp40) has been mooted as a potential vaccine candidate [29] and its
increased transcription after drug treatment gives support to the idea that any vaccine based
on egg antigen may be enhanced by treatment with PZQ to stimulate production of the target
antigen by the pathogen.
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2

4

S-PZQ

R-PZQ

Smp_174240:hypothetical protein
Smp_041730:putative pre-mRNA-splicing factor cwc-21
Smp_140390:mixed-lineage leukemia protein
Smp_059210:hypothetical protein
Smp_141630.1:splicing factor 3b, subunit 1-related
Smp_102040.1:receptor for activated PKC
Smp_113310:hypothetical protein
Smp_132810:IPR001092 Basic helix-loop-helix dimerisation region bHLH
Smp_049300.1:putative major egg antigen
Smp_049240:putative heat-shock protein beta-1
Smp_067430:basic helix-loop-helix protein
Smp_016550.1:putative gtp-binding protein hflx
Smp_049300.2:putative major egg antigen
Smp_176870:cd63 antigen-like
Smp_195070:conserved Schistosoma protein
Smp_186020:putative heat shock protein
Smp_206250:unnamed protein product
Smp_049300.3:putative major egg antigen
Smp_170740:hypothetical protein
Smp_149750:hypothetical protein
Smp_160610:hypothetical protein
Smp_172460:hypothetical protein
Smp_094930:early growth response protein
Smp_123260:putative ubiquitin 1
Smp_049250:putative heat shock protein-HSP20/alpha crystallin family
Smp_130370:elongation of fatty acids protein 1
Smp_143590:hypothetical protein
Smp_043580:putative histone-lysine n-methyltransferase
Smp_129510:hypothetical protein
Smp_162300:matrix metallopeptidase-9
Smp_170620:hypothetical protein
Smp_134870:putative early growth response protein
Smp_138210:hypothetical protein
Smp_079770.1:putative protein disulfide-isomerase ER-60 precursor
Smp_039490.1:hypothetical protein
Smp_143510:cut-like 1
Smp_083430:hypothetical protein
Smp_201330:unnamed protein product
Smp_036270.1:putative arginine/serine-rich splicing factor
Smp_014400.1:enhancer of polycomb
Smp_157690:putative von Willebrand factor type A domain-containing protein
Smp_066820.1:putative dice1/dead/h box polypeptide
Smp_128350:hypothetical protein
Smp_158740:hypothetical protein
Smp_122820:hypothetical protein
Smp_045650:putative intersectin-1
Smp_042440:(dihydro)ceramide Synthase
Smp_044870:putative zinc finger protein
Smp_180890:hypothetical protein
Smp_194380:putative core 1 udp-galactose
Smp_146580:putative homeobox protein knotted-1
Smp_079380:serine palmitoyltransferase 2
Smp_130510:hypothetical protein
Smp_129960:hypothetical protein
Smp_069170:putative cation efflux protein/ zinc transporter
Smp_044550.1:putative far upstream binding protein
Smp_018570:putative serine-rich repeat protein 2
Smp_142510.1:putative ribonuclease III
Smp_103140:putative alpha tubulin
Smp_136690:family S9 non-peptidase homologue
Smp_116760:hypothetical protein
Smp_021870:putative ccr4-associated factor
Smp_013570:hypothetical protein
Smp_159630:hypothetical protein
Smp_203090:uncharacterized protein
Smp_032320.1:putative serine/arginine rich splicing factor
Smp_026230:hypothetical protein
Smp_125510:putative cadherin

Fig 2. Expression of S. mansoni genes after treatment with R- and S-PZQ. Heat map of
all up-regulated genes in R and S-PZQ treated schistosomes relative to controls. Genes not
differentially expressed are colored grey. The color scale indicates log2 fold change in the
average of four biological replicates.
S5 Table. List of genes up-regulated after treatment of S. mansoni with R- or S-PZQ
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XM_Id

GeneDB_Id

log2FC

p-adj

NCBI_annotation

R-PZQ
XM_018792500.1

Smp_174240.1

5.484

1.751E-06

XM_018797184.1

Smp_041730.1

4.379

7.082E-03

XM_018794188.1
XM_018792424.1
XM_018791620.1
XM_018794745.1

Smp_141630.1
Smp_102040.1
Smp_140390.1
Smp_113310

4.117
3.882
3.474
3.219

1.245E-02
2.708E-03
1.441E-02
7.285E-03

XM_018791956.1

Smp_132810

3.053

3.744E-04

XM_018794696.1
XM_018794684.1
XM_018799842.1
XM_018797404.1
XM_018794700.1
XM_018791281.1

Smp_049300.1
Smp_049240
Smp_067430
Smp_016550.1
Smp_049300.2
Smp_176870

2.981
2.942
2.692
2.551
2.505
2.45

3.645E-21
1.659E-17
3.795E-04
2.902E-02
1.770E-02
1.189E-03

XM_018789885.1

Smp_195070

2.383

1.770E-02

XM_018794694.1
XM_018795708.1
XM_018794699.1
XM_018797437.1
XM_018796585.1
XM_018799180.1
XM_018798203.1
XM_018797509.1
XM_018797982.1

Smp_186020
Smp_206250
Smp_049300.3
Smp_170740
Smp_149750
Smp_160610
Smp_172460
Smp_094930
Smp_123260

2.123
1.991
1.854
1.798
1.694
1.597
1.561
1.544
1.543

9.412E-16
4.884E-02
6.074E-09
2.606E-03
2.151E-07
7.363E-03
3.193E-18
4.041E-10
2.694E-08

XM_018794689.1

Smp_049250

1.494

2.912E-13

XM_018799836.1
XM_018796297.1

Smp_130370
Smp_143590

1.484
1.471

6.736E-03
9.808E-03

XM_018797690.1

Smp_043580

1.468

9.501E-03

XM_018796971.1
XM_018799097.1
XM_018797880.1
XM_018795017.1
XM_018799619.1
XM_018799499.1

Smp_059210.1
Smp_129510
Smp_162300
Smp_170620
Smp_134870
Smp_138210

1.45
1.425
1.425
1.382
1.349
1.333

6.352E-04
1.484E-08
5.019E-04
4.603E-03
1.914E-09
1.342E-06

XM_018799452.1

Smp_079770.1

1.279

6.492E-03

XM_018797750.1
XM_018796310.1
XM_018790738.1
XM_018791691.1

Smp_039490.1
Smp_143510
Smp_083430
Smp_201330

1.273
1.27
1.249
1.247

9.980E-06
7.509E-03
2.150E-02
1.858E-03

XM_018794202.1

Smp_036270.1

1.243

1.371E-02

XM_018790795.1

Smp_014400.1

1.238

3.458E-03

XM_018789482.1

Smp_157690

1.217

1.146E-02

hypothetical protein
putative pre-mRNA-splicing factor cwc21
splicing factor 3b, subunit 1-related
receptor for activated PKC
mixed-lineage leukemia protein
hypothetical protein
Basic helix-loop-helix dimerisation
region bHLH
putative major egg antigen
putative heat-shock protein beta-1
basic helix-loop-helix protein
putative gtp-binding protein hflx
putative major egg antigen
cd63 antigen-like
conserved Schistosoma protein, unknown
function
putative heat shock protein
unnamed protein product
putative major egg antigen
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
early growth response protein
putative ubiquitin 1
putative heat shock protein-HSP20/alpha
crystallin family
elongation of fatty acids protein 1
hypothetical protein
putative histone-lysine nmethyltransferase
hypothetical protein
hypothetical protein
matrix metallopeptidase-9
hypothetical protein
putative early growth response protein
hypothetical protein
putative protein disulfide-isomerase ER60 precursor
hypothetical protein
cut-like 1
hypothetical protein
unnamed protein product
putative arginine/serine-rich splicing
factor
enhancer of polycomb, putative
putative von Willebrand factor type A
domain-containing protein
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XM_Id

GeneDB_Id

log2FC

p-adj

NCBI_annotation

XM_018793974.1
XM_018788885.1
XM_018788508.1
XM_018791522.1
XM_018797672.1
XM_018797081.1
XM_018795610.1
XM_018795382.1

Smp_066820.1
Smp_128350
Smp_158740
Smp_122820
Smp_045650
Smp_042440
Smp_044870
Smp_180890

1.202
1.199
1.189
1.152
1.148
1.144
1.138
1.127

1.397E-02
4.272E-05
8.512E-15
3.173E-03
6.359E-03
2.186E-02
9.686E-06
1.858E-03

XM_018795041.1

Smp_194380

1.116

2.480E-03

XM_018795673.1
XM_018793229.1
XM_018790009.1
XM_018788454.1

Smp_146580
Smp_079380
Smp_130510
Smp_129960

1.112
1.1
1.096
1.095

1.705E-02
7.032E-03
1.947E-05
8.077E-03

XM_018796790.1

Smp_069170

1.068

1.143E-03

XM_018788610.1

Smp_044550.1

1.059

6.359E-03

XM_018798920.1
XM_018797573.1
XM_018797511.1
XM_018791807.1
XM_018798673.1
XM_018795348.1
XM_018799096.1
XM_018798142.1
XM_018798499.1

Smp_018570
Smp_142510.1
Smp_103140
Smp_136690
Smp_116760
Smp_021870
Smp_013570
Smp_159630
Smp_203090

1.055
1.049
1.035
1.035
1.033
1.032
1.03
1.029
1.029

3.293E-06
1.739E-03
1.601E-03
3.669E-02
2.400E-04
4.788E-07
3.064E-04
1.247E-02
1.524E-02

XM_018790092.1

Smp_032320.1

1.02

1.501E-07

XM_018799314.1

Smp_026230

1.002

1.623E-04

putative dice1/dead/h box polypeptide
hypothetical protein
hypothetical protein
hypothetical protein
putative intersectin-1
(dihydro)ceramide Synthase
putative zinc finger protein
hypothetical protein
putative core 1 udp-galactose:nacetylgalactosamine-alpha-r beta 1,3galactosyltransferase
putative homeobox protein knotted-1
serine palmitoyltransferase 2
hypothetical protein
hypothetical protein
putative cation efflux protein/ zinc
transporter
putative far upstream (fuse) binding
protein
putative serine-rich repeat protein 2
putative ribonuclease III
putative alpha tubulin
family S9 non-peptidase homologue
hypothetical protein
putative ccr4-associated factor
hypothetical protein
hypothetical protein
uncharacterized protein
putative serine/arginine rich splicing
factor
hypothetical protein

XM_018797184.1

Smp_041730.1

4.338

7.465E-03

XM_018792500.1
XM_018791620.1
XM_018796971.1
XM_018796291.1

Smp_174240.1
Smp_140390.1
Smp_059210.1
Smp_125510

4.038
3.42
1.178
1.075

1.034E-02
3.103E-02
1.148E-02
6.607E-03

S-PZQ
putative pre-mRNA-splicing factor cwc21
hypothetical protein
mixed-lineage leukemia protein
hypothetical protein
putative cadherin

A total of 44 genes were down-regulated across both treatments and 22 were classed as
either hypothetical, uncharacterized or unnamed. (Fig. 3 and Table S6). Seven transcripts
were present in both the R- and S- transcriptomes and six of these were the most downregulated proteins in both data sets. Three of these six, Smp_152150, Smp_131110 and
Smp_014610, were hypothetical with log2 = -4.3, -4.2 and –3.3 respectively for R-PZQ and -
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9.9, -4.7 and -3.6 for S-PZQ treatment. The remaining 3 genes encoded a putative WDcontaining protein (Smp_032800), an eggshell precursor (Smp_000430) and eggshell protein
(Smp_191910). Lamberton et al. [30] noted that treatment with racemic PZQ had an effect on
worm fecundity as measured by the number of hatching eggs recovered from the spleen and
liver of infected mice. Down-regulation of eggshell proteins by both R- and S-PZQ treatment
(R-PZQ also down-regulated Smp_077890, Trematode eggshell synthesis domain containing
protein) suggests that any effect of the drugs on egg production may be independent of the
killing mechanism of the R-PZQ and an inherent property of both isomers.
Three transporter proteins were also down-regulated after treatment with R-PZQ
including a sodium/chloride dependent neurotransmitter transporter (Smp_160360, log2 = 1.2) and a putative glucose transporter (Smp_105410, log2 = -1.0). Of most note was the
down regulation of the ABC superfamily member ABCB1 (Smp_170820, log2 = -1.2).
Members of the ABCB, ABCC and ABCG subfamilies have previously been shown to
excrete structurally unrelated drugs and have the potential to confer drug resistance on cells
and organisms when aberrantly over expressed [31]. S. mansoni ABCB, ABC and ABCG
homologs, including Smp_170820, have been shown previously by us to be up-regulated in
juvenile schistosomes which are refractory to the drug [10]. In contrast there was little
evidence of transporter activity in mature schistosomes with the exception of a single
ABCB1 homolog (Smp_089200). Pinto-Almeida et al., [2015] found ABCB1 homolog
SmMDR2 (Smp_055780) to be up-regulated on exposure to PZQ, but in a PZQ resistant
strain. The absence of up-regulated ABC genes in the current study is consistent with our
previous findings when using standard S. mansoni PR1 that have not been selected for PZQ
resistance are exposed to the drug [10].
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-8 -6 -4 -2

S-PZQ

R-PZQ

Smp_032800.1:putative wd-repeat protein
Smp_152150:hypothetical protein
Smp_131110.1:hypothetical protein
Smp_000430.1:eggshell precursor protein
Smp_191910:eggshell protein
Smp_014610:hypothetical protein
Smp_028070.1:bicaudal D-like protein
Smp_077890:Trematode Eggshell Synthesis domain containing protein
Smp_073610.1:transcriptional co-activator crsp77-related
Smp_057410:hypothetical protein
Smp_152960:hypothetical protein
Smp_170150:hypothetical protein
Smp_152970:hypothetical protein
Smp_120920.1:hypothetical protein
Smp_198930:hypothetical protein
Smp_159470:hypothetical protein
Smp_203130:uncharacterized protein
Smp_129350:putative rab
Smp_160360:sodium/chloride dependent neurotransmitter transporter
Smp_000340:nuclear hormone receptor superfamily protein-related
Smp_051510:pericentrin fragment, putative
Smp_202970:uncharacterized protein
Smp_170820:ABCB1
Smp_150350:synaptotagmin
Smp_154180:hypothetical protein
Smp_103930.1:glycosyltransferase
Smp_135210:egf-like domain protein
Smp_173420:putative leucine-rich repeat-containing protein
Smp_201060:uncharacterized protein
Smp_051400:cytoplasmic dynein light chain
Smp_105410:putative glucose transport protein
Smp_108600:hypothetical protein
Smp_168140:hypothetical protein
Smp_157170:putative histidine kinase
Smp_025390:putative calcium-binding protein 2
Smp_129110.1:hypothetical protein
Smp_028070.1:bicaudal D-like protein
Smp_130100:saposin containing protein
Smp_195180:surface membrane antigen
Smp_203290:uncharacterized protein
Smp_203780:uncharacterized protein
Smp_201920:unnamed protein product
Smp_133180.1:putative zinc finger protein
Smp_194840:niemann pick c2

Fig 3. Expression of S. mansoni genes after treatment with R- and S-PZQ. Heat map of
all down-regulated genes in R and S-PZQ treated schistosomes relative to controls. Genes not
differentially expressed are colored grey. The color scale indicates log2 fold change in the
average of four biological replicates.
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S6 Table. List of genes down-regulated after treatment of S. mansoni with R- or S-PZQ
XM_Id

GeneDB_Id

log2FC

p-adj

NCBI_annotation

R-PZQ
XM_018795263.1

Smp_032800.1

-5.871

2.003E-11

XM_018791417.1

Smp_077890

-4.335

3.454E-02

XM_018793003.1
XM_018797389.1
XM_018790417.1
XM_018790420.1
XM_018795711.1

Smp_152150
Smp_131110.1
Smp_000430.1
Smp_191910
Smp_014610

-4.282
-4.181
-4.104
-3.546
-3.274

6.505E-03
2.085E-02
1.442E-02
2.684E-02
1.609E-02

XM_018793199.1

Smp_073610.1

-1.972

4.529E-02

XM_018798680.1
XM_018798679.1
XM_018790590.1
XM_018798678.1
XM_018793894.1
XM_018798598.1
XM_018788481.1
XM_018798004.1
XM_018799126.1

Smp_057410
Smp_152960
Smp_170150
Smp_152970
Smp_120920.1
Smp_198930
Smp_159470
Smp_203130
Smp_129350

-1.881
-1.866
-1.657
-1.62
-1.428
-1.377
-1.367
-1.29
-1.267

1.035E-09
1.648E-09
1.253E-09
3.336E-04
2.765E-02
1.793E-05
1.480E-02
4.047E-09
9.024E-09

XM_018789587.1

Smp_160360

-1.243

1.617E-04

XM_018794141.1

Smp_028070.1

-1.236

3.830E-05

XM_018791409.1

Smp_000340

-1.234

2.245E-03

XM_018792625.1
XM_018798000.1
XM_018788897.1
XM_018789676.1
XM_018791285.1
XM_018792740.1
XM_018789656.1

Smp_051510
Smp_202970
Smp_170820
Smp_150350
Smp_154180
Smp_103930.1
Smp_135210

-1.223
-1.22
-1.203
-1.165
-1.15
-1.101
-1.08

3.661E-08
7.146E-10
2.057E-04
1.253E-09
8.878E-04
1.610E-02
2.554E-03

XM_018793971.1

Smp_173420

-1.058

1.739E-03

XM_018794538.1
XM_018790629.1

Smp_201060
Smp_051400

-1.057
-1.038

4.204E-03
1.188E-05

XM_018795817.1

Smp_105410

-1.033

2.104E-05

XM_018790768.1
XM_018789841.1
XM_018789610.1
S-PZQ
XM_018795263.1
XM_018793003.1
XM_018797389.1
XM_018790420.1

Smp_108600
Smp_168140
Smp_157170

-1.029
-1.012
-1.002

2.160E-09
2.499E-02
6.558E-04

putative wd-repeat protein
Trematode Eggshell Synthesis
domain containing protein
hypothetical protein
hypothetical protein
eggshell precursor protein
eggshell protein
hypothetical protein
transcriptional co-activator
crsp77-related
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
uncharacterized protein
putative rab
sodium/chloride dependent
neurotransmitter transporter
bicaudal D-like protein
nuclear hormone receptor
superfamily protein-related
pericentrin fragment
uncharacterized protein
ABCB1
synaptotagmine
hypothetical protein
glycosyltransferase
egf-like domain protein
putative leucine-rich repeatcontaining protein
uncharacterized protein
cytoplasmic dynein light chain
putative glucose transport
protein
hypothetical protein
hypothetical protein
putative histidine kinase

Smp_032800.1
Smp_152150
Smp_131110.1
Smp_191910

-9.905
-4.726
-4.5
-4.467

3.268E-02
1.909E-03
1.411E-02
2.845E-02

putative wd-repeat protein
hypothetical protein
hypothetical protein
eggshell protein
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XM_Id

GeneDB_Id

log2FC

p-adj

NCBI_annotation

XM_018790417.1
XM_018795711.1

Smp_000430.1
Smp_014610

-4.423
-3.575

1.406E-02
5.692E-03

XM_018789515.1

Smp_025390

-2.226

8.802E-06

XM_018799286.1
XM_018794143.1
XM_018795705.1
XM_018797927.1
XM_018798695.1
XM_018794141.1
XM_018789716.1
XM_018791483.1
XM_018793438.1
XM_018790325.1

Smp_129110.1
Smp_028070.1
Smp_130100
Smp_195180
Smp_203290
Smp_028070.1
Smp_203780
Smp_201920
Smp_133180.1
Smp_194840

-1.594
-1.143
-1.093
-1.083
-1.065
-1.061
-1.05
-1.044
-1.017
-1.008

6.607E-03
1.627E-03
3.119E-09
1.304E-05
1.324E-02
3.557E-02
3.632E-04
2.845E-02
3.825E-02
2.801E-03

eggshell precursor protein
hypothetical protein
putative calcium-binding protein
2
hypothetical protein
bicaudal D-like protein
saposin containing protein
surface membrane antigen
uncharacterized protein
bicaudal D-like protein
uncharacterized protein
unnamed protein product
putative zinc finger protein
niemann pick c2

3.2.

RNA sequence validation

Quantitative real-time PCR (qRT-PCR) was employed to validate results obtained by RNASeq (S4 Fig). Five transcripts encoding homologs of ubiquitin 1 (Smp_123260), Collagen
alpha 1 (V) chain (Smp_170340), AMP-activated protein kinase gamma regulatory subunit
(Smp_144700), sodium/chloride dependent neurotransmitter transporter (Smp_160360), and
Thioredoxin 1 (Smp_008070) were validated based on their expression in S. mansoni after
treatment with R- and S-PZQ (S4A Fig). Patterns observed in the qRT-PCR data matched
those obtained in the RNA-Seq data set and showed significant correlation for R-PZQ (r =
0.982, p<0.0028; S4B Fig) and S-PZQ (r = 0.989, p<0.0014;S4 C Fig.]).
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RNA-Seq RPZQ

A

qRT-PCR RPZQ

Fold change (log2)

3

RNA-Seq SPZQ
qRT_PCR SPZQ

2
1
0
-1

0
08

07

0

B

Sm

p_
0

60

36

0
p_
1
Sm

p_
1

44

70

0
34
70
Sm

p_
1
Sm

Sm

p_
1

23

26

0

-2

C
3

3

p<0.0028

1

0

-1

-2

-2

-1
0
1
2
Relative expression level
Log2 (RNA-Seq)

Relative expression level
Log2 (qRT-PCR)

Relative expression level
Log2 (qRT-PCR)

r = 0.982

2

2

r = 0.989
p<0.0014

1

0

-1

-2

-1

0

1

Relative expression level
Log2 (RNA-Seq)

S4 Fig. Validation between RNA-Seq and qRT-PCR transcription of six expressed
genes.
(A) Log2 fold changes of expression of 5 selected S. manoni transcripts from R- and S-PZQ
treated parasites relative to control parasites assessed by RNA-Seq and qRT-PCR. qRT-PCR
fold changes were normalized to GAPDH (housekeeping gene), and gene expression profiles
at each point are the average of three biological replicates. Correlations between RNA-Seq
and qRT-PCR transcription each of the genes in (B) R-PZQ, and (C) S-PZQ were determined
using Pearson’s correlation.
4.

Conclusion
We observed that the anthelmintic enantiomer R-PZQ, induces a significantly greater

change in the transcriptome of S. mansoni than the inactive S-PZQ. With the parameters
employed, however, the number of DEGs in both data sets was relatively limited. For
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example, at the single, sub-lethal concentration tested we saw a significant induction of genes
encoding transcriptional regulatory proteins but surprising little evidence of a stress response
to either enantiomer. Enhanced transcriptional regulation comes as no surprise given our
previous findings that treatment of S. mansoni PR1 in vitro with 3 µM racemic PZQ
(effectively 1.5 µM of each enantiomer) for up to 20 h resulted in the differential expression
of 658 genes, including those involved in stress responses [9]. Similarly, we saw a stress
response in male S. mansoni exposed to a lethal dose of racemic PZQ in vivo [10]. While we
cannot be sure of the mouse plasma concentration of the enantiomers in this latter work, we
note that Andrews [32] calculated a maximum of 3 µM unmetabolized drug in plasma was
achieved in uninfected humans following administration of 46 mg/Kg with 1 µM (0.5 µM of
each enantiomer) the probable therapeutic threshold. Of course, it is possible the absence of
the stress response (or any significant change in expression of genes regulated by Ca2+influx)
in the experiment reported here is an indication that it is a synergistic effect of both
enantiomers and that each enantiomer individually may not have achieved a critical
intracellular threshold to trigger the response. As noted earlier, we will reanalyze our data
omitting the single outlying data point from the control and each of the treated groups. This
may improve the sensitivity of our analysis and provide a larger cohort of DEGs to analyze.
Alternatively, we have used relatively conservative cut off values for assigning a gene as
differentially expressed or not and using a more liberal approach may yield a more
informative data set (a baby and bathwater conundrum). Also, both enantiomers may actually
have had only relatively minor effects on transcription dynamics or we may also have used a
dose of each enantiomer that was too low to be effective. Our previous in vitro experiments
with racemic PZQ suggests these latter scenarios to be unlikely [9], however, a final
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conclusion on the respective effects of each enantiomer on the S. mansoni transcriptome will
only be made after further analysis.
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Abstract
Schistosomiasis is an intravascular parasitic infection estimated to affect over 206 million
people, the majority of whom live in Africa where the trematode worms Schistosoma
mansoni and Schistosoma haematobium are the major causative agents. While a number of
drugs have been used to treat schistosomiasis, praziquantel (PZQ) is the only one that is
widely available, relatively cheap, and easy to use. The reliance on a single drug for the
treatment of such a prevalent disease is a cause for concern due to the potential for resistance
to render PZQ ineffective. In this study, we examine the transcriptome of three generations of
a laboratory strain of S. mansoni (PR1) whose susceptibility to PZQ has been diminished
across 9 passages through exposure to increasing sub-lethal doses of the drug. Miracidial
susceptibility was significantly reduced after exposure to 2 x 50 mg/Kg PZQ during the first
passage. Susceptibility of worms in vivo was first assessed during passage 5 when mice
infected with PZQ-selected schistosomes were dosed with a lethal dose of 3 x 300 mg/Kg
PZQ resulting in only a 10% reduction in worm number compared to control treatment. The
emergence of reduced sensitivity was marked by a shift in sex ratio from a predominantly
male to a female population, a reduction in the length of females and ultimately the loss of
the PZQ-selected line after passage 9. Analysis of differentially regulated transcripts did not
suggest that any particular gene product or pathway was associated with drug resistance
suggesting either a loss of function mutation to a single gene or an epistatic interaction of
multiple gene products as the underlying cause of reduced susceptibility.
Keywords: Praziquantel, Schistosoma, drug resistance, schistosomiasis, helminth,
transcriptome
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1. Introduction
Schistosomiasis is a chronic neglected parasitic disease caused by digenetic blood flukes
of the genus Schistosoma. As of 2016, the disease was estimated to affect approximately 206
million people worldwide though it is most prevalent in sub-Saharan Africa where
Schistosoma mansoni and Schistosoma haematobium are the major causative agents [1]. This
is a significant improvement on the previous estimate of approximately 259 million infected
in 2014 [2]. One reason for this decline is that the number of individuals receiving treatment
for the disease has risen from approximately 62 million in 2014 to 89 million in 2016 [1,2].
Praziquantel (PZQ) is the most widely available drug for the treatment of schistosomiasis
and remains effective against all schistosomes that infect humans [3]. While PZQ has been
used for over 30 years the exact mechanism of action of the drug remains unknown. One
drawback is that sexually immature, juvenile schistosomes are resistant to its action [4,5]
and, as the drug is usually administrated in endemic areas as a single dose, complete
effectiveness is unlikely with a reservoir of PZQ resistant juvenile parasites likely remaining
in the host.
With no other readily available treatment options, and as the number of PZQ tablets
dispensed increases each year, there are significant concerns that the drug’s usefulness may
be diminished or lost to resistance. A number of reports of schistosomes with reduced PZQ
sensitivity have appeared in the literature though not all of these document increasing
resistance. For example, Stelma et al. [6] reported a cure rate of only 18% with PZQ in
Senegal in 1991 and suggested PZQ resistance as one explanation, however, Fallon et al. [7]
reported that isolates from this population had a slower maturation rate rendering the
schistosomes less sensitive to the drug at the times tested. Of more concern were the eight
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isolates derived from Egyptian patients who had received multiple, curative doses of PZQ
[8]. These had less sensitivity to the drug compared to controls and retained reduced
sensitivity over multiple passages through mice. In a subsequent study, William et al., [9]
found 3 of the 6 strains retained reduced PZQ sensitivity in the absence of selective PZQ
pressure but this came at the cost of diminished reproductive fitness which may account for
the failure to find PZQ resistance in the same area of Egypt 10 years after the initial finding
[10]. Melman et al. [11] reported a correlation between the number of PZQ treatments
received by Kenyan patients and the sensitivity of miracidia hatched from eggs isolated form
patient fecal samples. Similar to the experience reported by William et al. [9], a line of S.
mansoni derived from one patient that showed reduced PZQ sensitivity could not be
maintained in the lab beyond a few generations.
While it has proven difficult to find and maintain PZQ resistant Schistosoma spp. in field
isolates, resistance has been successfully generated in the laboratory by maintaining
schistosomes in mice with exposure to increasing sub lethal doses of PZQ over several
generations [12-15]. The S. mansoni isolates generated by Coeli et al. [13] were also unstable
and showed reduced genetic diversity. Remarkably, Couto et al. [16] generated S. mansoni
with reduced sensitivity after one exposure to PZQ in infected snails.
The molecular mechanism underpinning resistance in field or laboratory-induced isolates
is unknown and it may be that there is more than one route to reduced sensitivity. ATPbinding cassette (ABC) proteins, which are known to be involved in the transport of a wide
variety of compounds, including drugs, across membranes have been implicated in the
natural resistance of juvenile S. mansoni [17-20]. We have suggested that the aberrant
expression of ABC transporters may underlie acquired resistance in adults [21] and, using a

91

laboratory selected strain of PZQ resistant S. mansoni Pinto-Almeida et al. [15] demonstrated
the involvement of ABC transporter SmMDR2, belonging to the ABCB1 (Pgp-like)
subfamily, in male worms displaying the resistance phenotype.
As indicated above, PZQ resistance has been shown to come with a fitness tradeoff
[9,11,13,22], and may provide one explanation for the absence of sustained PZQ resistance in
the field where there is a large refugium of drug sensitive schistosomes. As the number of
individuals treated with PZQ continues to rise, the question of resistance in field isolates
remains important for both researchers and government agencies trying to implement policy
for the control of schistosomiasis. In the absence of alternative drugs or a vaccine, and as the
number of PZQ tablets dispensed continues to rise [1], a better understanding of PZQ
resistance is needed to understand the risk that it poses. Here we present data that outlines the
production of a PZQ-selected line of S. mansoni with reduced susceptibility to the drug and
chart the change in the transcriptome of the line over 3 passages in comparison to drug
sensitive controls.

2. Materials and Methods
2.1.

Ethics statement
All animal procedures in this study were reviewed and approved by the University of

New Mexico Institutional Animal Care and Use Committee. This study followed the U.S.
National Institutes of Health’s Guide for the Care and Use of Laboratory Animals.

2.2.

Experimental procedures for selection of reduced PZQ sensitivity in S. mansoni
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Passage 1: Thirty Swiss Webster (SW) 10–12 week old outbred male mice (Charles River,
Kingston, NY) were each infected percutaneously with 100-150 S. mansoni Puerto Rican 1
(PR1) cercariae. Mice were randomly divided into 2 groups of 15 and treated by oral gavage
at 35 and 37 days post infection (dpi) with either 2% Cremaphore EL (Sigma-Aldrich, St.
Louis, MO) in aqueous suspension (control group) or 50 mg/kg PZQ (PZQ-selected group) in
aqueous suspension with 2% Cremaphore EL. Mice were euthanized and perfused with
RPMI 1640 media (RPMI; Sigma-Aldrich) at 49 dpi. Adult parasites were collected by
perfusion, counted and sexed, then placed in RNeasy lysis buffer with 1% 2-mercaptoethanol
(Sigma-Aldrich) and stored at -80 °C for RNA isolation. In addition, 10 parasites of each sex
and treatment were chosen randomly and placed in RPMI for measurement of their length
and breadth (see below).
After perfusion, mouse livers were harvested for egg collection. The eggs were pulse
blended in artificial spring water (ASW) and placed under direct light for 1 h to hatch.
Miracidia were collected, pooled and used to infect 24 laboratory reared Biomphalaria
glabrata for each treatment group by exposing individual snails to 5 miracidia overnight.
Snails were housed in 10-gallon tanks in ASW and after 8 weeks placed in individual wells
under direct light to induce cercarial shedding. Cercariae from each treatment were pooled
and used to infect mice as described above.
Passage 2–9: For each successive passage (P), groups of 10 SW mice were infected
percutaneously with 100-150 S. mansoni PR1 cercariae per mouse derived from either the
PZQ-selected or control line of the previous generation. Animals in the control group
received 2% Cremaphore EL in aqueous suspension and those in the selected group received
PZQ with the dose and time of treatment varying depending on the passage number.
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Mice were perfused and euthanized at 49 dpi and the parasites and livers processed as
described for P1. Miracidia derived from eggs obtained from livers of PZQ-selected or
control mice were used to found the next generation of PZQ-selected and control
schistosomes respectively. A 2-way ANOVA followed by a Sidak’s multiple comparisons
test was used to compare the number of recovered parasites from the control and PZQselected groups across each passage. All statistical analyses were conducted using GraphPad
Prism (GraphPad Software Inc., La Jolla, CA).

2.3.

Dimensions of S. mansoni
Parasites (n = 10 parasites/sex/treatment/generation) were photographed 1 h after

perfusion using a Zeiss SteREO Discovery V12 microscope and AxioCam HRc camera (Carl
Zeiss Microscopy, Thornwood, NY). Parasite length and breadth were measured using
AxioVision 4.8.2 software (Carl Zeiss Microscopy) with at least 3 and up to 5 measurements
made per worm for length and breadth. The significance of observed differences between
control and PZQ-selected parasites across sex and generation was assessed using 2-way
ANOVA followed by Sidak’s multiple comparisons test.

2.4.

In vivo assay of S. mansoni PZQ resistance
From P5 onwards, to estimate the effectiveness of the PZQ dosing regime in producing

drug resistant parasites, mice were infected with approximately 100-150 control or PZQselected cercariae (n = 5 per group) derived from the previous generation and subsequently
received 3 doses of 300 mg/kg PZQ by oral gavage at 28, 35 and 37 dpi. The mice were
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perfused and euthanized at 49 dpi and the number of parasites that survived counted and
parasite burden reduction calculated using the following modified formula [11]

% parasite burden reduction =
(Mean # adult parasites in treatment group) – (Mean # parasites in adult assay) x 100
Mean # adult parasites in treatment group

A 2-way ANOVA followed by Sidak’s multiple comparisons test was used to compare
the number of recovered parasites from the control and selected groups across generations.

2.5.

PZQ susceptibility assay of S. mansoni miracidia
Miracidia were tested for PZQ sensitivity using a modified version of the protocol

developed by Melman et al. [11]. Three to five PZQ-selected or control miracidia were
placed in 40 µL ASW in up to 12 wells of a 96-well plate with a final concentration of 0 or
10-5 M PZQ. Dimethyl sulfoxide (DMSO) at 1% was used to prepare 10-4 M PZQ stock and
all wells received a final concentration of 0.1% DMSO including those with no drug. A
dissecting microscope was used to observe the miracidia prior to administration (t=0) and
after 20 min incubation. Miracidia were counted blind as alive or dead i.e. remained
immobile. The percentages of surviving miracidia were calculated as described by Mwangi et
al. [14]. The surviving miracidia percentages were compared using a multiple t-test with the
Holm-Sidak method.

2.6.

RNA isolation and sequencing
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Isolation of parasite total RNA was performed using an RNeasy Mini Kit (Qiagen,
Redwood City, CA) according to the manufacturer’s instructions and included incubation
with RNase-free DNase (Qiagen) followed by RNA cleanup and concentration (Zymo
Research, Irvine, CA).
A

B

C

D

E

F

S1 Fig. Total RNA qualitative and quantitative analysis. Bioanalyzer results showing total
RNA gel-image (left) with ladder for reference and electrogram (right) from representative
samples (A) P6 control, (B) P6 PZQ-selected, (C) P7 control, (D) P7 PZQ-selected, (E) P8
control, and (F) P8 PZQ-selected. FU = fluorescent units, and s = retention time in seconds.
Total RNA was quantified and quality assessed using a Qubit Fluorometer (Thermo
Fisher Scientific, Waltham, MA) and Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA)
respectively. Bioanalyzer traces from each generation and treatment showed no significant
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RNA degradation (Supplementary Figure 1; S1 Fig.). RNA was stored at -80 °C until
required.
RNA sequencing (RNA-Seq) was performed on 4 biological replicates of control and
PZQ-selected schistosomes from P6, 7, and 8 using an Illumina NextSeq 500 instrument
(Illumina, San Diego, CA). Libraries and indexing were prepared using the KAPA mRNA
HyperPrep kit (KAPA Biosystems, Wilmington, MA) following the manufactures
instructions. A Qubit Fluorometer and KAPA Library Quantification Kit for Illumina
Platform were employed to quantify the libraries. The quality and fragment size for each
library was examined with the Agilent 2100 Bioanalyzer. Samples passing quality control
were pooled and sequenced to generate 150 base paired-end reads at the Molecular Biology
Core Facility, University of New Mexico, NM.

2.7.

RNA-Seq data processing

Raw sequence reads were trimmed and filtered using Trimmomatic v0.36 [23] with a slide
window of 4 nucleotides, average score above 20 and minimum length of 36 nucleotides.
Reads passing filters were mapped to the S. mansoni transcriptome annotated from assembly
GCA_000237925.2 ASM23792v2 (NCBI) using Bowtie2 v2.2.9 [24]. Gene expression
levels were estimated using RSEM v1.2.31 [25] and differential gene expression analysis
performed using DESeq2 v 1.18.1 [26] EdgeR v 3.20.8 [27], and EBSeq v1.18.0 [28].
Results were organized using SARTools [29] with cutoffs for all programs set at an adjusted
p ≤0.05 with log2 fold change of either <-1 (down-regulated genes) or >1 (up-regulated
genes). Differentially expressed gene (DEG) lists for the average (4 replicates per
treatment/generation) of each treatment resulting from each program were displayed by Venn
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diagram and only genes common to at least two bioinformatic approaches were retained for
further analysis. All sequencing data sets generated for this study were deposited with Gene
Expression Omnibus and can be accessed through accession number GSE120682.

2.8.

Functional annotation
DEG lists and annotation file S. mansoni ASM23792v2 were imported into Blast2GO

v5.0.13 [30] to classify genes with ontology terms in order to identify functionality. We
performed Fisher’s Exact Test (FET) with multiple corrections to identify Gene Ontology
(GO) terms significantly (p < 0.05) over-represented in the DEG list compared to the whole
gene set [31].

2.9.

Quantitative real-time PCR
RNA samples for quantitative real-time PCR (qRT-PCR) originated from the

corresponding samples used for RNA-Seq in order to validate Illumina data set expression
patterns. Genes were chosen based on qRT-PCR primers passing efficiency tests and their
differential expression patterns at P6-8. qRT-PCR was performed on 1 µg total RNA reverse
transcribed to cDNA (20 µL reactions) using the iScript cDNA Synthesis Kit (Bio-Rad
Laboratories, Hercules, CA) according to the manufacturer’s instructions. All qRT-PCR
reactions were performed in biological triplicates with technical duplicates using
SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad Laboratories). Each 20 µL
reaction contained of 100 ng cDNA and 0.5 µM primer. Reactions were performed using a
C1000 96 Touch Thermo Cycler (Bio-Rad Laboratories) using S. mansoni gene qRT-PCR
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primers (S1 Table) designed with the Integrated DNA Technologies OligoAnalyzer tool
(www.idtdna.com).

S1 Table. Primers used in S. mansoni quantitative real-time PCR reactions

Gene ID

Gene

Forward Primer

Reverse Primer

Smp_056970

SmGAPDH

GTCATTCCAGCACTAAACGG

CCTTCCCTAACCTACATGTCAG

Smp_144000

Cytochrome
oxidase C subunit

GCCATCCTCAACCATTTGCC

ACCCGTTTCCAATGACTCGC

Smp_119130

Cercarial
elastase

TTCTCACACTGAGGAACGGC

ATCCACTGAGTGTCTGTGCG

Smp_062250

Myosin 2
light chain

TTTATTTCCCCCGGACAGGC

AGCCGCTTATCGTCTTACCG

Smp_180180

SIL 1

ATCGCCATCTGGTTTCGAGC

AGGATTCGAACCCGTAAGCC

Smp_197070

Kinesin
protein K1F6

GCTGAGGGATAGTTTAGGCGG

ATTAAGGCAACACGCTGTGC

Smp_191310

Histone
deacetylase 4

CATGCAGAACCAGGTCAAGC

TGATCGAACAGGGTGGTTGC

Cycling conditions for S. mansoni gene expression were as follows; 95 °C for 10 min
followed by 40 cycles at 95 °C for 15 s, 60 °C for 1 min and 60 °C for 20 s. CFX Manager™
Software v3.1 (Bio-Rad Laboratories) was used to calculate fold change (2-ΔΔCt method)
relative to the reference glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.
Expression of this gene did not vary significantly between treatment groups (S2 Table).

S2 Table. Real-time PCR cycle threshold (Cq) raw data for S. mansoni reference gene GAPDH
Biological
Well
Fluor
Target
Content
Sample
Cq
Cq Mean
Cq Std. Dev
Set Name
A01
SYBR GAPDH Unkn-01
P6_S1
PZQ-selected
20.79
20.79
0.007
A02

SYBR

GAPDH

Unkn-01

P6_S1

PZQ-selected
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20.78

20.79

0.007

A03

SYBR

GAPDH

Unkn-02

P6_S2

PZQ-selected

19.98

19.99

0.008

A04

SYBR

GAPDH

Unkn-02

P6_S2

PZQ-selected

19.99

19.99

0.008

A05

SYBR

GAPDH

Unkn-03

P6_S3

PZQ-selected

20.30

20.32

0.033

A06

SYBR

GAPDH

Unkn-03

P6_S3

PZQ-selected

20.35

20.32

0.033

A07

SYBR

GAPDH

Unkn-04

P6_C1

control

20.14

20.10

0.057

A08

SYBR

GAPDH

Unkn-04

P6_C1

control

20.06

20.10

0.057

A09

SYBR

GAPDH

Unkn-05

P6_C2

control

19.49

19.50

0.014

A10

SYBR

GAPDH

Unkn-05

P6_C2

control

19.51

19.50

0.014

A11

SYBR

GAPDH

Unkn-06

P6_C3

control

18.93

18.92

0.013

A12

SYBR

GAPDH

Unkn-06

P6_C3

control

18.91

18.92

0.013

B01

SYBR

GAPDH

Unkn-07

P7_S1

PZQ-selected

19.84

19.83

0.015

B02

SYBR

GAPDH

Unkn-07

P7_S1

PZQ-selected

19.81

19.83

0.015

B03

SYBR

GAPDH

Unkn-08

P7_S2

PZQ-selected

18.52

18.54

0.036

B04

SYBR

GAPDH

Unkn-08

P7_S2

PZQ-selected

18.57

18.54

0.036

B05

SYBR

GAPDH

Unkn-09

P7_S3

PZQ-selected

19.18

19.14

0.055

B06

SYBR

GAPDH

Unkn-09

P7_S3

PZQ-selected

19.11

19.14

0.055

B07

SYBR

GAPDH

Unkn-10

P7_C1

control

20.40

20.39

0.014

B08

SYBR

GAPDH

Unkn-10

P7_C1

control

20.38

20.39

0.014

B09

SYBR

GAPDH

Unkn-11

P7_C2

control

20.15

20.16

0.009

B10

SYBR

GAPDH

Unkn-11

P7_C2

control

20.16

20.16

0.009

B11

SYBR

GAPDH

Unkn-12

P7_C3

control

19.44

19.43

0.002

B12

SYBR

GAPDH

Unkn-12

P7_C3

control

19.43

19.43

0.002

C01

SYBR

GAPDH

Unkn-13

P8_S1

PZQ-selected

20.70

20.65

0.074

C02

SYBR

GAPDH

Unkn-13

P8_S1

PZQ-selected

20.60

20.65

0.074

C03

SYBR

GAPDH

Unkn-14

P8_S2

PZQ-selected

20.27

20.28

0.016

C04

SYBR

GAPDH

Unkn-14

P8_S2

PZQ-selected

20.30

20.28

0.016

C05

SYBR

GAPDH

Unkn-15

P8_S3

PZQ-selected

20.65

20.62

0.041

C06

SYBR

GAPDH

Unkn-15

P8_S3

PZQ=selected

20.59

20.62

0.041

C07

SYBR

GAPDH

Unkn-16

P8_C1

control

19.14

19.14

0.001

C08

SYBR

GAPDH

Unkn-16

P8_C1

control

19.14

19.14

0.001

C09

SYBR

GAPDH

Unkn-17

P8_C2

control

19.11

19.10

0.020

C10

SYBR

GAPDH

Unkn-17

P8_C2

control

19.09

19.10

0.020

C11

SYBR

GAPDH

Unkn-18

P8_C3

control

19.20

19.18

0.026

C12

SYBR

GAPDH

Unkn-18

P8_C3

control

19.16

19.18

0.026

Statistical analysis was performed using a Student’s t-test for normalized gene expression
between treatment groups, and Pearson’s correlation was used to examine the correlation
between qRT-PCR and RNA-Seq data.
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3. Results and Discussion

3.1.

Selection of praziquantel resistance in S. mansoni
The initial goal of this study was to select for a PZQ resistant line of S. mansoni using a

modification of the protocol employed by Fallon and Doenhoff [12]. In the original protocol,
isolates of S. mansoni from Puerto Rico, Brazil, Kenya and Egypt were used to provide
sufficient genetic variation to facilitate selection of resistance after 6 passages with
increasing drug pressure. Using a similar protocol, we were able to induce resistance in S.
mansoni derived from 7 Kenyan field isolates within 5 generations [14]. In contrast, at least 2
other studies have generated PZQ resistant schistosomes by selecting on a single (LE) strain
[13,16]. Due to the success of these latter experiments in selecting for resistance on
(probable) limited genetic variation, we chose S. mansoni PR1 as the sole source of genetic
material for our experiments. Survival of at least 90% of schistosomes after exposure to 3 x
300 mg/kg PZQ on 28, 35 and 37 dpi was chosen as the indicator of acquisition of PZQ
resistance as we found that this regime would reduce PR1 burden from 69.3 + 2.5
schistosomes in control mice to 1.3 + 2.3 in PZQ treated mice 10 days after the final
treatment (P < 0.0001). This was also the drug regimen chosen in 2 previous studies to assess
drug resistance [12,13]. The number and gender of parasites recovered across 9 passages
from control and PZQ-selected treatment lines are shown in Table 1.
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Table 1. Worms recovered from S. mansoni infected mice after treatment with PZQ over 9 passages
Passage

Treatment (mg/kg PZQ)

Mean + SD
Total No. of worms

Male:Female

1

2 x 50a

36 + 36
42 + 22

1.11
1.16

2

2 x 100a

43 + 17
31 + 19

1.52
1.21

3

2 x 200a

23 + 4
40 + 17

1.55
2.00

4

2 x 250a

47 + 8
40 + 17

2.23
0.74

5

3 x 300b

51 + 11
42 + 21

1.68
0.62

6

3 x 300b

22 + 9
36 + 15

1.20
0.90

7

3 x 300b

35 + 17
26 + 5

1.92
0.59

8

3 x 300b

44 + 13
27 + 10

1.32
0.80

9

20 + 4
1.86
3 x 300b
17 + 6
0.31
a
PZQ in 2% Cremaphore EL or 2% Cremaphore EL alone were administered at 35 and 37 dpi by oral gavage.
b
PZQ in 2% Cremaphore EL or 2% Cremaphore EL alone were administered at 28, 35 and 37 dpi by oral
gavage.

During P1-4, administration of 50-250 mg/kg PZQ administered on 35 and 37 dpi did not
result in a significant reduction of parasite burden compared with the control group. Through
the first 3 passages there was a male bias in both treatment groups which is in accord with the
sex distribution associated with bisexual infection [32]. By P4, however, the PZQ-selected
group showed a female bias for the first time. Beginning P5, the dose of PZQ was increased
to 3 x 300 mg/kg on days 28, 35 and 37 dpi. Egg laying begins at around 28 dpi and this
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earlier start to treatment ensured that few eggs were deposited prior to the application of drug
pressure. Again, there was no significant difference in the number of worms recovered from
PZQ treated and control mice at 49 dpi and, as with P4, drug pressure during P5-9 resulted in
a female bias that was not observed with the control treatment. For example, after P9 there
were 13 + 3 male and 7 + 2 female worms isolated form the control line but 4 + 2 male and
13 + 4 females from the PZQ-selected line. Two earlier studies also observed a decrease in
male/female ratio following PZQ treatment [22,33]. One explanation could be that female
parasites are less susceptible to PZQ in vivo due simply to reduced exposure to the drug as
they sit in the male gynecophoric canal. Alternatively, reduced PZQ sensitivity may be an
inherent trait and Pica-Mattoccia and Cioli [4] observed that the in vitro ED50 of immature
females derived from bisexual infections is three times that of male parasites while Shaw and
Erasmus [34] reported that the tegument of male worms is more susceptible to PZQ than that
of females. The observation of reduced female sensitivity is not universal. Coeli et al. [13]
found more males in the 11th passage of LE strain worms selected for PZQ resistance
suggesting sex selection through drug pressure may be a more complex phenomenon than
can be explained simply by the sensitivity or degree of exposure of each sex to the drug.
To confirm that the PZQ-selected line had reduced sensitivity to the drug, mice infected
with either the PZQ-selected or control lines were treated with 3 x 300 mg/kg PZQ on days
28, 35 and 37 dpi, euthanized at 49 dpi and the number of surviving worms calculated (Table
2).
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Table 2. Percentage reduction in parasite burden of control and selected parasites in passages 5-9 after
treatment with PZQ.
Passage (P)_Line

P5_control
P5_PZQ-selected
P6_control
P6_PZQ-selected
P7_control
P7_PZQ-selected
P8_control
P8_PZQ-selected
P9_control
P9_PZQ-selected

Treatment
PZQ (mg/kg)

Mean ± SD Parasite
number

-

51.0 ± 11

3 x 300a

27.8 ± 15

-

41.7 ± 20.5

3 x 300

37.4 ± 11.6

-

21.9 ± 8.9

3 x 300

3.8 ± 3.0

-

35.6 ± 15.3

3 x 300

36.5 ± 10.5

-

34.9 ± 17

3 x 300

19.6 ± 5.2

-

26.2 ± 4.8

3 x 300

31.8 ± 3.7

-

43.6 ± 13.0

3 x 300

14.2 ± 4.1

-

27.4 ± 9.9

3 x 300

21.8 ± 2.1

-

19.9 ± 4.3

3 x 300

12.6 ± 4.7

-

16.9 ± 5.8

% Reduction

Statistical Significance (pvalue)

46

0.0006b

10

NSc

83

0.0063

0

NS

44

0.0201

0

NS

67

<0.0001

20

NS

37

NS

4
NS
3 x 300
16.2 ± 5.6
a
PZQ was administered on 28, 35 and 37 dpi. Animals were euthanized and worm burden counted at 49 dpi.
b
Statistical significance of parasite burden in control and PZQ-selected lines was determined using the HolmSidak method with alpha = 0.05.
c
NS = not significant.

While there was a 46 (P < 0.001) and 83% (P < 0.01) reduction in worm burden of
control line mice, there was only a non-significant 10 and 0% reduction in the PZQ-selected
line at P5 and 6 respectively. Similar significant reductions were seen in the control line at P7
and 8 but not in the PZQ line. Although there was a 37% reduction in worm burden in the
control line at P9, this failed to reach statistical significance and there was only a 4%
reduction in worm burden in the PZQ line at this point. These results confirm that after the
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5th passage the PZQ-selected line had become significantly less susceptible to the drug and
this status was maintained until P9.
Unfortunately, we were unable to maintain the PZQ-selected line after P9 as the few eggs
that were extracted from the liver of infected mice did not hatch. This is similar to the
experience of Coeli et al. [13] who lost their line after 11 passages. Loss may be due to a
trade-off between PZQ ‘resistance’ and fitness cost [9] and/or a skewed sex ratio leading to a
loss of fecundity [13,22] as observed in this study.
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Fig. 1. Changes in S. mansoni length and width during PZQ-selection. The length and
width of male and female schistosomes isolated during passages (P) 1-9 are shown. (A)
Length of male parasites. (B) Width of male parasites. (C) Length of female parasites. (D)
Width of female parasites. Significance of observed differences between control and PZQselected schistosomes were assessed with 2-way ANOVA with Sidak’s multiple comparisons
test. Error bars represent mean with standard deviation, n = 10 sex/treatment/passage. * = p<
0.05, and *** = p< 0.001.
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In addition to the shift towards females from P4 onwards, we also observed that while the
length (Fig. 1A) and width (Fig. 1B) of PZQ-selected and control male worms did not differ
over the 9 passages, females became significantly shorter in the PZQ-selected cohort
compared to controls from P6 onwards (Fig. 1C). The greatest difference was seen at P8
where the female schistosomes in the control line had a mean length of 5751.8 + 654.2 µm
compared to 4150.4 + 440.3 µm (p < 0.001) in the PZQ-selected line. At P9, the mean length
of females was 5832.9 + 790.7 µm, while those from the PZQ-selected line were 4336.2 +
599.9 µm (p < 0.001). No differences in the width of female worms were observed between
the two groups (Fig. 1D). While these data are suggestive of a fitness cost we cannot rule out
that the stunted growth was due to the female schistosomes apparent need for the presence of
males to reach maturity [35].
In vitro treatment of miracidia hatched from control and PZQ-selected eggs were
assessed for their ability to survive 20 min exposure to 10-5 M PZQ as an indication of PZQ
sensitivity. Remarkably, our results suggest the PZQ-selected miracidia were less susceptible
to the drug after the first exposure of the adults to 2 x 50 mg/kg on 35 and 37 dpi and across
most subsequent generations tested (P3, 4, 6, 7 and 8) with the exception of P5 (Fig. 2 A-G).
The rapid acquisition of reduced miracidial PZQ sensitivity was surprising to us and contrary
to the observation of Mwangi et al. [14] who only observed a reduction in sensitivity after
exposure of mouse infections to 2 x 250 mg/kg during P4 and 3 x 300 mg/kg during P5.
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Fig. 2. In vitro assay of S. mansoni miracidia survival after exposure to PZQ. Miracidia
were hatched from control and PZQ-selected groups and exposed to 10-5 M PZQ for 20 min
and the number surviving counted. (A) P1, (B) P3, (C) P4, (D) P5, (E) P6, (F) P7, and (G)
P8. Passage 2 and P9 data are not included due to low miracidia yield. Statistical significance
determined between control and PZQ-selected parasites using the Holm-Sidak multiple
comparisons method with alpha = 0.05. Error bars represent mean with standard deviation. *
= p< 0.05, ** = p< 0.01, and *** = p< 0.001.
Overall, our results suggest that sexually mature S. mansoni PR1 had acquired
significantly reduced sensitivity to PZQ by the completion of P5 and this was maintained
through P9. Thus, transcriptomic analysis of adult schistosomes from control and PZQselected lines was undertaken to identify genes associated with reduced sensitivity.

3.2.

Transcriptome sequencing and analysis
To compare changes in the S. mansoni transcriptome, cDNA libraries were prepared from

pooled, mixed sex schistosomes derived from 10 mice infected with PZQ-selected or control
lines at P6, 7 and 8. On removing adapter sequences and any ambiguous, low quality reads
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(Q < 20), a total of 315 million 150 base paired end reads were obtained. In each of the six
groups the mean number of reads was between 11.5 (P8, PZQ-selected) and 17.8 million (P6,
control), and a mean of 50.0% (P8, PZQ-selected) and 62.5% (P6 & P7, control) paired reads
mapped to the S. mansoni genome (S3 Table). Each group contained 4 biological
replicates/generation and the number of reads provided enough coverage for differential
expression analysis [36].
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S3 Table. Summary of Illumina read counts and mapped reads for each sequenced sample.

Sample

Total quality-trimmed
paired reads (Q>20)

Percentage of S. mansoni
mapped reads

P6_control_1

12339139

58.19

P6_control_2

15513283

60.32

P6_control_3

21353821

64.83

P6_control_4

21804032

66.45

P6_PZQ-selected_1

17696542

54.65

P6_PZQ-selected_2

17776418

53.11

P6_PZQ-selected_3

16234697

49.94

P6_PZQ-selected_4

18644407

56.74

P7_control_1

11574274

56.91

P7_control_2

12202288

60.08

P7_control_3

28374988

71.75

P7_control_4

15019608

61.18

P7_PZQ-selected_1

16431003

58.61

P7_PZQ-selected_2

11591609

59.04

P7_PZQ-selected_3

17144399

59.61

P7_PZQ-selected_4

15186746

58.48

P8_control_1

14402932

65.05

P8_control_2

13869791

62.85

P8_control_3

15254212

59.26

P8_control_4

16732065

62.06

P8_PZQ-selected_1

12841503

48.60

P8_PZQ-selected_2

11488047

49.26

P8_PZQ-selected_3

11443465

50.54
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Sample

Total quality-trimmed
paired reads (Q>20)

Percentage of S. mansoni
mapped reads

P8_PZQ-selected_4

10289245

51.22

Principle Component Analysis (PCA) resulted in transcriptomes of the PZQ-selected and
control groups segregating broadly into two distinct regions with individual transcriptomes
generally clustering with others from their treatment/control group. P6 PZQ-selected samples
were the most diverse with two of the 4 samples clustering more with the control selected
samples than PZQ-selected (S2 Fig). All samples were retained for further analyses to
maintain an n of 4 across all groups.
15
P6_control
P6_PZQ-selected

10

P7_control

PC2: 19%

5

P7_PZQ-selected
P8_control
P8_PZQ-selected

0
-5
-10
-15
-15

-10

-5

0

5

10

15

PC1: 41%

S2 Fig. Principal component analysis. Two-dimensional principal component (PC) analysis
was used to characterize the scattering or clustering of replicates in each treatment groups.
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S3 Fig. Venn diagrams displaying selection of differentially expressed genes in this
study. Three programs (DESeq, EBSeq, and EdgeR) were employed to identify differentially
expressed genes in PZQ-selected schistosomes compared to controls. Only differentially
expressed genes (DEG) that were seen in at least two of these programs were analyzed
further. Separated DEGs in this study are shown in each triangle, (A) P6 up-regulated, (B) P6
down-regulated, (C) P7 up-regulated, (D) P7 down-regulated, (E) P8 up-regulated, and (F)
P8 down-regulated.
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Three programs (DESeq, EBSeq, and EdgeR) were used to identify differential transcript
expression and PZQ-selected samples were normalized to control samples for each
generation. The number of DEGs observed using each program is shown in S3 Fig and
transcripts that were identified by at least 2 of the programs were retained for further
analyses. Both the number of up- and down-regulated DEGs increased with each successive
generation (S4 Table) with a total of 197, 652 and 1003 DEG identified at P6, 7 and 8
respectively.

S4 Table. Number of all differentially expressed genes for passages (P) 6, 7, and 8.

Passage

No. of upregulated genes

No. of down-regulated
genes

P6

43

154

P7

301

351

P8

375

628

The number of DEGs present across all 3 generations was small in comparison to the
total numbers with only 7 up-regulated and 13 down-regulated genes shared across P6-8 (Fig.
3).
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A
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P8

P8

327

489

24

17
P6
19

7
0

30
P7

96

271

P6
40

13
5

P7
303

Fig. 3. Venn diagrams of differentially expressed genes. Indicated in the Venn diagrams
are the numbers of (A) up-regulated and (B) down-regulated differentially expressed genes
shared between or exclusive to S. mansoni derived from P6, P7 and P8. The diameter of each
circle is proportional to the number of transcripts it represents.
Gene Ontology (GO) analysis was employed to provide a statistical assessment of overrepresented GO Biological Process terms and S. mansoni reference sequences. The overrepresented up-regulated sequences in PZQ-selected schistosomes were weighted towards
cell cycling processes at P7 but had no other obvious discernable pattern (S4A, C and E Fig).
The over-represented down-regulated sequences were overwhelmingly involved in metabolic
processes across P6-8: (S4B, D and F Fig) with 8 transcripts designated as ‘drug metabolic
process’ being amongst most overrepresented sequence at P7. On further examination 4 of
these were hypothetical proteins while the remaining transcripts encoded putative pyruvate
kinase (Smp_065610), adenosine kinase (Smp_008370), phosphatidylcholine-sterol
acyltransferase (Smp_082120) and a kunitz-type protease inhibitor (Smp_180810). Overall,
however, it was difficult to discern a significant pattern in the GO data related to selection for
PZQ resistance.
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S4 Fig. Functional classification of differentially regulated transcripts. Blast2GO was
employed to categorize up- and down-regulated differentially expressed transcripts into
Biological Process (BP) according to Gene Ontology (GO) terms. Enrichment analysis was
performed with Fisher’s Exact Test (p<0.05) to identify over-representation of sequences
compared to reference annotation and results of the top 10 are shown in (A) P6 up- and (B)
down-regulated transcripts, (C) P7 up- and (D) down-regulated transcripts, and (E) P8 upand (F) down-regulated transcripts. Some sequences are present in multiple categories.
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3.3.
-4

Expression analysis of transcripts related to PZQ-selection
-2

0

2

4
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Smp_000290:female-specific protein 800 (fs800) partial mRNA
Smp_152150:hypothetical protein partial mRNA
Smp_029620:putative homeobox protein SMOX-4 partial mRNA
Smp_139700:putative retinal dehydrogenase partial mRNA
Smp_093790:CAI-2 protein, putative partial mRNA
Smp_026810:scavenger receptor class B type-2 (sr-B2),putative partial mRNA
Smp_191910:eggshell protein, putative partial mRNA
Smp_112450:trematode eggshell synthesis domain containing protein partial mRNA
Smp_186130:hypothetical protein partial mRNA
Smp_081820:synaptic glycoprotein sc2 related partial mRNA
Smp_125990:hypothetical protein partial mRNA
Smp_000130:hormone-sensitive lipase (S09 family) partial mRNA
Smp_049600:putative DNAj (hsp40) homolog, subfamily C, member partial mRNA
Smp_016230:cadherin-related partial mRNA
Smp_161830:hypothetical protein partial mRNA
Smp_013040:cathepsin D (A01 family) partial mRNA
Smp_141800:putative oxalate:formate antiporter partial mRNA
Smp_196080:putative gpcr partial mRNA
Smp_094930:early growth response protein, putative partial mRNA
Smp_134870:putative early growth response protein partial mRNA
Smp_172460:hypothetical protein partial mRNA
Smp_116800:putative hemicentin partial mRNA
Smp_065610:putative pyruvate kinase partial mRNA
Smp_111340:hypothetical protein partial mRNA
Smp_154010:hypothetical protein partial mRNA
Smp_047660:putative ferritin partial mRNA
Smp_157380:hypothetical protein partial mRNA
Smp_206250:unnamed protein product partial mRNA
Smp_157010:putative titin partial mRNA
Smp_013570:hypothetical protein partial mRNA
Smp_124340:hypothetical protein partial mRNA
Smp_072330:putative heat shock protein partial mRNA
Smp_085310:26S proteasome regulatory subunit S3, putative partial mRNA
Smp_055740:putative nanos RNA binding domain partial mRNA
Smp_145200:putative engrailed partial mRNA (SMOX-2)
Smp_084450:hypothetical protein partial mRNA
Smp_017290:hypothetical protein partial mRNA
Smp_206060:unnamed protein product partial mRNA
Smp_106930:putative heat shock protein 70 partial mRNA
Smp_076320:hypothetical protein partial mRNA
Smp_137080:putative RNA-binding protein partial mRNA
Smp_193730:hypothetical protein partial mRNA
Smp_127360:hypothetical protein partial mRNA
Smp_166690:hypothetical protein partial mRNA
Smp_017080:zinc finger CCCH type with G patch
Smp_154420:putative clathrin heavy chain partial mRNA
Smp_090930:hypothetical protein partial mRNA
Smp_172960:putative kunitz-type protease inhibitor partial mRNA
Smp_093830:hypothetical protein partial mRNA
Smp_025700:putative rab9p40 partial mRNA

Fig. 4. Expression of selected S. mansoni genes during passages (P) 6, 7 and 8. Heat map
of the 50 most differentially expressed genes (25 up- and 25 down-regulated) in PZQselected parasites relative to controls. Genes not differentially expressed are colored gray and
increased and decreased gene expression are teal and pink respectively. The color scale
indicates log2 fold change for the average of four biological replicates.
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A heat map was constructed to examine those genes that showed the greatest levels of
differential regulation in the PZQ-selected versus control lines at P6-8 (Fig. 4). The top 25
up– and 25 down-regulated genes were selected based on their expression at any of these 3
passages. Twenty genes encoded ‘hypothetical’ or ‘unnamed’ proteins underlining the
relative paucity of original annotation of Schistosoma spp. genes as well as the evolutionary
distance between Schistosoma spp. and the classical model organisms. Only 4 genes showed
expression in S. mansoni at more than one passage and only two (both hypothetical) showed
expression across all three passages. Among the highly differentially regulated genes with
functional annotation there were some interesting observations. Two of the putative gene
products were similar to transcriptional regulator Homeobox proteins engrailed-like SMOX2 (Smp_145200) and SMOX-4 (Smp_029620), two other products matched the putative
DNA-binding Early Growth Response Protein (EGRP; Smp_094930 and Smp_134870) and
two encoded homologs of RNA binding proteins (Smp_055740 and Smp_137080). While
SMOX-2 and both RNA binding proteins were up-regulated in P7, both EGRP genes were
down-regulated at this time and SMOX-4 was down-regulated at P8. These changes in
expression of transcriptional and post-transcriptional regulators presumably reflect the
increased transcriptional dynamics associated with the PZQ-selected line and are indirect
consequences of drug selection. Other genes of note included the reproduction associated
genes encoding female-specific protein 800 (Smp_000290) which is mooted to play a role in
vitellogenesis [37], eggshell protein (Smp_191910) and trematode eggshell synthesis domain
containing protein (Smp_112450), each of which were down- regulated only at P8, perhaps
presaging the loss of the PZQ-selected line due to the lack of viable egg production.
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Although the mechanism of action of PZQ and the molecular basis of juvenile resistance
is not yet understood, previous studies have identified gene products that may play a role in
both [18-20,38,39]. We have examined the differential regulation of a number of these genes
previously and identified a number of stress related genes that are differentially regulated in
response to PZQ exposure in vitro [19] and in vivo [20]. One of these, ferritin (Smp_047660),
was highly up regulated in juvenile and sexually mature male S. mansoni after exposure to 4
x 250 mg/kg/day over 4 consecutive days but was among highly down-regulated genes at P7
(Fig. 4). In addition to ferritin, one other transcript encoding a previously identified PZQ
induced stress protein transcript, thioredoxin peroxidase (TPX-1; Smp_059480), was also
down- regulated at P7 (log2 change = -1.16, p<0.05). No other stress transcripts that have
been identified previously as being differentially regulated in response to PZQ treatment
were significantly altered though a number of other heat shock proteins that can also be
responsive to stress (Smp_106930, Smp_072330 and Smp_049600) were significantly upregulated at P7 or P8.
ABC superfamily members, especially those of the ABCB, ABCC and ABCG families
have been shown repeatedly to excrete structurally unrelated drugs, potentially conferring
multiple drug resistance on cells in which they are expressed [40]. At least 21 ABC
transporter genes have been identified in S. mansoni [41] and we found four of these to be
differentially regulated including 3 members of the ABCB and ABCC subfamilies. PintoAlmeida et al. [15] examined a stable resistance phenotype to PZQ and found the relative
expression of the ABCB1 homolog SmMDR2 (Smp_055780) increased in PZQ resistant
strain males compared to susceptible strain while resistant strain female SmMDR2 levels
were actually lower than the susceptible strains. We identified this ABCB1 homolog
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previously to be highly up-regulated in drug resistant mixed sex juveniles but not adult males
[20]. In this study, Smp_055780 was not differentially regulated but this may be explained by
the significantly higher number of females than males contributing to our data set. In addition
to identifying an increase in the expression of Smp_055780, Sanchez et al. [20] also
identified significant increases of a second ABCB1 homolog (Smp_089200) in mixed sex
juveniles but not a third (Smp_170820). Here, a fourth ABCB1 homolog, Smp_137080, was
up-regulated at P7 (1.94, p<0.05). S. mansoni subfamily homologs ABCC4 (Smp_167610)
and ABCC10 (Smp_147250) were also differentially regulated at P7, however, while
ABCC10 expression was decreased at P7 (-1.45, p<0.5), ABCC4 was increased (1.04,
p<0.05). Therefore, while drug resistance in juvenile worms may be associated with
increased expression of ABCB, ABCC and ABCG family members [20] there is only limited
evidence from this data set that reduced susceptibility in P6-8 schistosomes is associated with
the overexpression of ABC subfamily members. Each of these differences between previous
and current data sets may, however, be due to the sampling of the transcriptome in this study
having taken place 12 days after the last PZQ treatment rather that in the period immediately
after the last administration of the drug allowing the protective stress and ABC transporter
response induced acutely on drug exposure to dissipate as the PZQ is metabolized. If true,
this would also infer that reduced susceptibility may be the result of changes in facultative
rather than constitutive expression states.
Pinto-Almeida et al. [39] revealed proteins associated with S. mansoni PZQ resistance
through comparative proteomics. PZQ resistance was generated in a fully susceptible
isogenic S. mansoni strain treated with 0.3 µM PZQ and compared to a fully susceptible
strain using high throughput LC-MS/MS identification of protein spots after 2-dimensional
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gel electrophoresis. Of the eight proteins Pinto-Almeida and colleagues identified in the
mixed sex PZQ-resistant strain, none were identified in our data set though one of the three
proteins associated with PZQ-resistance exclusive to females, a receptor for activated Protein
Kinase C was down-regulated in P8 (Smp_102040; -1.10, p<0.05).

3.4.

RNA-Seq validation
Quantitative real-time PCR (qRT-PCR) was employed to validate results obtained by

RNA-Seq analysis. Six transcripts encoding homologs of cytochrome oxidase C
(Smp_144000), cercarial elastase (Smp_119130), myosin 2 light chain (Smp_062250), SIL 1
(Smp_180180), kinesin K1F6 (Smp_197070) and histone deacetylase (Smp_191310) were
validated based on their differential expression across P6, 7 and 8 (S5A Fig). Patterns
observed in the qRT-PCR data mirrored those obtained by the RNA-Seq data and showed
significant correlation at P6 (r = 0.85, p <0.0312; S5B Fig), P7 (r = 0.98, p <0.0007; S5C
Fig) and P8 (r = 0.98, p <0.0005; S5C Fig).
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S5 Fig. Comparison and correlations between RNA-Seq and qRT-PCR analysis of six
differentially expressed genes. (A) log2 fold changes of expression in 6 selected S. mansoni
transcripts from PZQ-selected parasites relative to controls for each of six genes assessed by
RNA-Seq and qRT-PCR at P6-8. qRT-PCR fold changes were normalized to GAPDH. Gene
expression profiles at each point are the average of three biological replicates. Correlations
between RNA-Seq and qRT-PCR transcription for the six genes in (B) P6, (C) P7, and (D)
P8 were determined using Pearson’s correlation.
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4.

Conclusions
The underlying basis for the reduction in sensitivity to PZQ seen in this study could have

a number of explanations. For example, there may be one or more mutations in a single gene,
such as that encoding the PZQ binding target, that causes a loss of function without a change
in expression. Alternatively, a mutation or epigenetic change in a single gene may lead to a
change in its expression, which can in turn alter the toxicity and/or half-life of a drug. While
the transcriptomic analysis carried out here did provide insight into genes that are
differentially regulated between PZQ-selected and sensitive lines it did not immediately
suggest any single candidate gene or pathway as being responsible for reduced susceptibility.
For example, while there were some differences in expression of ABC transporters that might
enhance drug efflux, there was not enough consistency in expression for any single ABC
gene to suggest that this superfamily alone played a significant role. William et al. [9]
concluded the factors leading to selection and maintenance for PZQ resistance varied among
isolates and a third drug resistance mechanism may be, as Roquis et al., [42] suggested, ‘due
to the epistatic interaction of multiple gene products rather than an (epi)mutation of a single
locus’. For example, S. mansoni resistance to the anthelmintic drugs hycanthone and
oxamniquine emerged readily in natural populations [43]. A single autosomal recessive locus
was found to encode both oxamniquine and hycanthone resistance in two strains [44] and
subsequently, non-synonymous coding mutations associated with a sulfotransferase gene
were identified, thus establishing the mechanism of resistance for both of these compounds
[45]. Subsequently, however, Roquis et al. [42] found laboratory generated hycanthoneresistant parasites that do not carry these mutation but instead carry a high number of
epigenetic changes compared to controls. Changes in chromatin structure between resistant
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and sensitive worms were identified and 5 genes involved in stress responses and one ABC
transporter were among 69 genes associated with these modifications. Thus, while we also
see changes to stress, ABC transporter, and Receptor for activated PKC gene expression, like
Roquis et al. [42] and Pinto-Almeida et al. [39] we also see no obvious single gene or
pathway behind the observed PZQ resistance in S. mansoni PR1 and therefore do not rule out
the possibility of such an ‘epistatic interaction of multiple gene products’. Identifying the true
genetic actors in such interactions may need either more powerful transcriptomic or
proteomic analyses or meta-analyses as well as a systems approach to understanding of the
role of epigenetics in the generation of resistance. In addition, the mechanism by which
resistance is generated may differ depending on whether relatively genetically homogeneous
laboratory strains are targeted for selection as opposed to heterogeneous field populations in
which the classic monogenic pattern of resistance can more easily arise.
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CONCLUSIONS
Schistosomiasis significantly impacts the lives of more than 206 million individuals
with more than half comprised of children (WHO, 2017). As we come upon more then
fifteen years of mass drug administration (MDA) program implementation, the number of
people treated for this diseases has increased greatly with 62 million individuals treated in
2014 compared to 89 million in 2016 (WHO, 2017), resulting in significant gains being
achieved (Hotez and Aksoy, 2017). With the drug praziquantel (PZQ) being at the heart of
control and currently no alternative options available, a better understanding of PZQ is
needed in order to sustain progress and continue control and eventually eliminate the disease.
The goal of this research was to apply transcriptomics to provide a better understanding of
the effect PZQ on schistosomes.
The first goal for this dissertation was to provide a comprehensive study of how PZQ
affects the host-parasite interaction. Therefore we analyzed livers from S. mansoni infected
mice that were treated with PZQ or drug vehicle in order to provide transcriptomic profiles in
the presence or absence of granulomas. The results revealed the presence of immune and
fibrotic responses in both PZQ and vehicle treated mice, but severe pathology was present in
the mice where PZQ was absent. Additionally the classic T helper 1 (Th1) response followed
by a T helper 2 (Th2) upon increase in egg burden was seen in vehicle, even though the PZQ
treated mice had significant reduction in the egg burden the immune response was similar,
perhaps explained by antigens released from dying parasites.
Additionally we examined S. mansoni’s response in the host-parasite interaction
using quantitative real-time PCR to investigate the ATP-binding Cassette (ABC) transporter
genes in both juvenile and adult parasites treated with PZQ in vivo. Results revealed that
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members of the ABC-B, -C, and -G family transporter genes were transcriptionally enriched
in juvenile parasites compared to adult. Prior research (Kasinathan et al., 2010; Kasinathan et
al., 2014) has suggested that ABC transporters may play a role in the resistance of juveniles
to PZQ and our study provided support for this hypothesis.
The second objective was the investigation of adult male S. mansoni exposed to the
individual R- and S-PZQ enantiomers. Using transcriptomic analysis we found 101
differentially regulated transcripts in R-PZQ treated parasites compared to only 22 in S-PZQ
treated parasites compared to controls. The enantiomers only shared a total of 11
differentially expressed transcripts, up-regulated = 4 and down-regulated = 7. Furthermore SPZQ treated parasites only had one differentially expressed transcript (Smp_125510, putative
cadherin) compared to 63 in R-PZQ treated parasites, with 26 labeled as hypothetical or
uncharacterized proteins. We observed more transcripts (up- and down-regulated) in R-PZQ
compared to S-PZQ, perhaps exposing the dissimilarity in the anthelmintic activity between
the enantiomers. This analysis is still at an initial stage, however, and we may have to revise
and ease the constraints for calling genes differentially regulated in order to gain further
detail in the response profiles.
The last objective was to investigate the molecular basis for reduced PZQ sensitivity
in S. mansoni. Selection pressure through increasing doses of PZQ was continuously applied
to S. mansoni throughout nine passages, and resulted in a reduced susceptibility of miracidia
after one passage and a significantly reduced susceptibility of sexually mature S. mansoni
during passages five though eight. There was a marked shift in sex ratio starting at passage
five and continuing through passage nine resulting in more females compared to males in the
PZQ-selected line. Additionally the parasite’s size was recorded throughout the study and
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females had a significant reduction in length compared to control parasites. We lost the PZQ
insensitive isolates after passage 9, an observation seen by Coeli et al (Coeli et al., 2013)
after passage 11. Loss could also suggest parasites have reduced fitness associated with PZQ
resistance (William et al., 2001), or the skewed sex ratio leads to a loss of fecundity (Coeli et
al., 2013; Lamberton et al., 2017). Transcript analysis revealed reduced PZQ sensitivity was
not associated with any specific gene or pathway profiles, perhaps suggesting that reduced
PZQ sensitivity is a combination of epigenetic modifications in multiple gene products and a
single loss of function mutation to a key gene in the drugs mechanistic pathway.
The research in this dissertation provides extensive, novel transcript profiles of S.
mansoni and its murine host in the presence and absence of PZQ. Ultimately the three large
data sets produced will provide a resource for future analyses and meta-analyses of the hostpathogen-drug interaction.
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a b s t r a c t
Schistosomiasis is a neglected tropical disease caused by blood-dwelling flukes of the genus Schistosoma.
While the disease may affect as many as 249 million people, treatment largely relies on a single drug, praziquantel. The near exclusive use of this drug for such a prevalent disease has led to concerns regarding
the potential for drug resistance to arise and the effect this would have on affected populations. In this
study, we use an in vitro assay of drug sensitivity to test the effect of praziquantel on miracidia hatched
from eggs obtained from fecal samples of Kenyan adult car washers and sand harvesters as well as school
children. Whereas in a previous study we found the car washers and sand harvesters to harbor Schistosoma mansoni with reduced praziquantel sensitivity, we found no evidence for the presence of such
strains in any of the groups tested here. Using miracidia derived from seven car washers to infect snails,
we used the shed cercariae to establish a strain of S. mansoni with significantly reduced praziquantel sensitivity in mice. This was achieved within 5 generations by administering increasing doses of praziquantel
to the infected mice until the parasites could withstand a normally lethal dose. This result indicates that
while the threat of praziquantel resistance may have diminished in the Kenyan populations tested here,
there is a strong likelihood it could return if sufficient praziquantel pressure is applied.
! 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction
Schistosomiasis is a water-borne parasitic disease that affects
more than 249 million people (World Health Organization, 2014)
with a global disease burden calculated at 24–56 million disability-adjusted life-years lost (King, 2010). Of the limited number of
drugs available to treat schistosomiasis, praziquantel (PZQ) is the
least expensive and easiest to use (Hagan et al., 2004) and, since
PZQ is highly effective against all schistosome species that infect
humans, its use in mass treatment campaigns has grown significantly. In 2006, approximately 12 million people were treated with
PZQ and by 2012 this number reached approximately 42 million
(World Health Organization, 2014). While the drug is highly effective against sexually mature forms of the parasite it is often unable
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to cure infections due to its inability to kill juvenile schistosomes at
2–4 weeks post-infection (Pica-Mattoccia and Cioli, 2004; Aragon
et al., 2009). As PZQ is often administered with a significant time
lapse measured in months or years between treatments this can
leave a significant reservoir of schistosomes infecting people that
are unaffected by the drug. This, combined with continuing exposure to the parasite, means the drug can often only provide shortterm relief from infection. Despite this drawback, PZQ remains the
only readily available treatment for schistosomiasis amid concern
that as it becomes more widely dispensed, drug resistance traits
may emerge thus removing the most effective, albeit flawed drug
from the limited treatment options available.
There have been a number of in vivo and in vitro studies documenting differential sensitivity of Schistosoma mansoni isolates to
PZQ. For example, a relatively low cure rate was reported during
a study of PZQ efficacy and side effects in Senegal in 1991
(Stelma et al., 1995). A subsequent study of a field isolate derived
from snails in the same geographical area suggested that, when
compared with two isolates from Puerto Rico and Kenya, the Senegal isolate matured in mice at a significantly slower rate thus
likely rendering it less susceptible to the drug at the times tested
(Fallon et al., 1997). Ismail et al. (1999) generated 12 S. mansoni

http://dx.doi.org/10.1016/j.ijpddr.2014.09.006
2211-3207/! 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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isolates from patients who had failed to be cured by 3 doses of PZQ
that would normally prove effective. These isolates were maintained in mice and 8 were found to have a significantly higher
ED50 than controls as well as a significantly diminished contractile
response in vitro. In a related study, 3 of 6 isolates retained their
decreased response to PZQ after several passages through the life
cycle in the absence of PZQ (William et al., 2001). In addition, these
isolates had an associated diminished reproductive fitness suggesting reduced PZQ sensitivity may have come with a significant biological cost. In a study using miracidial assays to determine PZQ
sensitivity, Lamberton et al. (2010) noted that S. mansoni hatched
from eggs obtained from the feces of children after two or more
PZQ treatments were more likely to survive in vitro exposure to
the drug compared with those from newly infected children.
Although this may point to a variation in susceptibility of adult S.
mansoni worm survival to repeated drug treatment, it may also
reflect differential susceptibility to PZQ of eggs at different stages
of maturity as they pass through the host. While treatment failure
has been reported in travellers returning from areas endemic for
Schistosoma haematobium (Mendonca da Silva et al., 2005; Alonso
et al., 2006), a study of individuals infected with S. haematobium
on Pemba Island, Tanzania found no indication of PZQ resistance
as determined by egg counts and miracidial viability after 20 years
of mass drug administration (Guidi et al., 2010).
Fallon and Doenhoff (1994) were able to induce PZQ resistance
in the laboratory by exposing a pool of S. mansoni isolates from
Puerto Rico, Brazil, Kenya and Egypt that had been maintained in
the laboratory for up to 10 years to increasing sub-curative doses
of PZQ. Mice infected with the 6th generation of selected cercariae
were then treated with 3 ! 300 mg/kg doses at days 28, 35 and 37
after infection, and showed only a 7% reduction in worm burden
compared with an 88% reduction in mice infected with nonselected worms. Coeli et al. (2013) infected mice with S. mansoni
(LE strain) and treated with PZQ following a protocol based on
Fallon and Doenhoff (1994) to generate worms with similarly
reduced drug sensitivity. This led to a decrease in genetic heterogeneity suggesting that multi-generational PZQ exposure resulted in
reduced population diversity. When schistosomes of the drugselected strain were bred with those of an unselected strain, the
F1 offspring were found to have intermediate PZQ sensitivity suggesting the reduced susceptibility trait was co-dominant (PicaMattoccia et al., 2009). Couto et al. (2011) were able to generate
S. mansoni with reduced PZQ susceptibility within a single life cycle
by feeding PZQ to snails harboring the parasite.
Clearly, while studies of PZQ resistance have to take into account
confounding factors such as the rate of schistosome maturity as well
as individual variations in drug metabolism and immune competency, the development of reduced susceptibility to PZQ is a real possibility. Here, we examine the in vitro susceptibility of miracidia
hatched from eggs derived from fecal samples of patients living in
two regions of Kenya endemic for schistosomiasis. In addition, we
used some of these miracidia to establish an S. mansoni laboratory
isolate with significantly reduced susceptibility to PZQ.
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Kisumu, western Kenya. Both groups spend significant periods
of time in the water of Lake Victoria or the surrounding streams
as part of their occupation. All adults enrolled for this study came
from one of these two groups and all had previously been treated
with PZQ with the year of last treatment being between 2006 and
2013.
From 2004 to 2007, collaboration between the Kenya Medical Research Institute (KEMRI) and Japan International Cooperation Agency administered a school-based schistosomiasis and
soil-transmitted helminth control project in Mwea, central
Kenya. The project dispensed annual doses of dewormers
including PZQ to all school-aged children in the region regardless of their infection status. Thereafter, the National Deworming Program took over the control activities, and has
continued with annual treatment of children since 2012 to date.
In this study, enrolled students were between 5 and 16 years of
age and were from three primary schools: Thiba, MbuiNjeru
and Mukou. Children were sampled in June 2013 or February
2014 with the date of last treatment within 1 year of sample
collection.
Fecal samples were tested for S. mansoni eggs using the modified Kato Katz technique. Miracidia obtained from eggs in positive
fecal samples from individual patients were used to estimate their
in vitro sensitivity to PZQ and to establish a line of S. mansoni with
reduced sensitivity to PZQ.
The KEMRI Scientific and Ethical Committees and the Institutional Review Board of the University of New Mexico approved this
study. All adults and the parents or guardians of the children
involved provided informed consent.
2.2. PZQ susceptibility assay of miracidia derived from fecal samples
Miracidial sensitivity to PZQ was tested in vitro using a modified
version of the technique developed by Liang et al. (2001). Freshly
hatched miracidia derived from stools of sand harvesters (n = 24),
car washers (n = 14) or school children (n = 34) were placed in each
well (4–6 miracidia per well) of a 96-well microtitre plate in 40 ll
aged tap water. Each row represented a single group of miracidia
and received either 0, 10"6 or 10"5 M PZQ. PZQ was prepared as
a stock solution of 10"4 M in 1% DMSO and the final concentration
of DMSO was 0.1% in all wells including the control. The mean
number of groups of miracidia used per patient per concentration
of PZQ was 19.2 (range: 6–42). This was dependent on the number
of miracidia obtained from a fecal sample. Miracidia were observed
with a dissecting microscope prior to (0 min) and 20 min after the
addition of PZQ. An independent observer, who had no knowledge
of the miracidial source or PZQ concentration used, recorded the
number of dead miracidia. Miracidia were assumed dead if they
remained immobile. The percentage of miracidia mortality after
treatment for 20 min with 10"6 and 10"5 M PZQ was calculated
as follows:

ðMean No: live miracidia from control groupÞ " ðMean No: live miracidia from treated groupÞ ! 100
Mean No: live miracidia from control group

2. Materials and methods

2.3. Snail sampling and parasite propagation in mice

2.1. S. mansoni egg collection from fecal samples of infected
individuals to obtain miracidia

In addition to testing PZQ sensitivity of S. mansoni miracidia
from parasite eggs of naturally infected individuals, miracidia
derived from cercariae shed from naturally infected, field-collected
Biomphalaria snails were also tested after passage through
laboratory mice. Biomphalaria spp. were collected from sites where

Isolates of S. mansoni were recovered from eggs in fecal samples of adults working as car washers or sand harvesters in
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schistosomiasis is known to be endemic including Lake Victoria
shores at Kisumu and Asao stream, both in western Kenya as well
as Kibwezi stream in southern Kenya and the Mukou and Nice Rice
irrigation ditches at Mwea, in central Kenya. Snails were washed
and separated into 24-well plates with aged tap water for up to
3 days with intermittent inspection for the appearance of S. mansoni cercariae using a dissecting microscope. Shedding snails were
pooled and approximately 100 cercariae were used to infect each
of 2–3 outbred mice. At 49 days post-infection, S. mansoni eggs
were obtained from the mouse livers and hatched in aged tap
water. PZQ sensitivity of hatched miracidia was assessed using
the assay outlined above.
All animal experimentation complied with the policies, regulations and guidelines mandated by the Institutional Animal Care
and Use Committees of the University of New Mexico and KEMRI.
2.4. Generation of an S. mansoni laboratory strain with reduced PZQ
susceptibility
Miracidia were hatched from eggs retrieved from fecal samples
obtained from 7 car washers and combined. This pool was used to
infect Biomphalaria sudanica and the cercariae shed subsequently
used to infect outbred mice. An isolate with reduced sensitivity
to PZQ was established after 5 generations with exposure to
increasing doses of PZQ essentially as described by Fallon and
Doenhoff (1994) with the following differences. Briefly, 10 outbred
mice were infected with approximately 100 cercariae and randomly distributed into two groups and treated with either
100 mg/kg/day PZQ in 2.5% Cremophor EL (Sigma, USA) (n = 5) or
an equivalent volume of 2.5% Cremophor EL vehicle alone (n = 5)
on each of days 28 and 35 post infection. 3 weeks after the final
dose of PZQ or vehicle, mice were perfused with RPMI medium
and the number of worms counted. Statistical analysis of differences in worm yield from PZQ treated and vehicle treated mice
was calculated using an unpaired Student’s t-test assuming equal
variance.
For each passage, eggs from the liver that survived PZQ treatment (selected) or vehicle treatment (non-selected) were used to
infect B. sudanica and the cercariae subsequently used to infect
the next generation of mice. This protocol was repeated for the second passage with the dose of PZQ being increased to 200 and
250 mg/kg/day for the third and fourth passages. Mice in the 5th
passage received 300 mg/kg/day on days 28, 35 and 37 post-infection. In addition, mice infected with non-selected S. mansoni
received 2 ! 200 and 2 ! 250 mg/kg PZQ on days 28 and 35 postinfection (passages 3 and 4) and 3 ! 300 mg/kg PZQ on days 28,
35 and 37 post-infection (passage 5) to establish lethality of the
drug at these concentrations for the isolates being selected upon.
PZQ sensitivity of hatched miracidia obtained after each
passage was assessed using the protocol described above.

Approximately 6 drug-selected miracidia were placed in each of
48 wells of a 96 well microtitre plate. Twenty four wells were treated with 10"5 M PZQ and an additional 24 with the same volume of
PZQ vehicle and observed after 0 (pretreatment control), 10 and
20 min by an independent observer. Non-selected miracidia were
treated identically. The percentage of drug selected or non-selected
miracidia surviving at each time point after treatment was calculated as follows:

Mean No: live miracidia from PZQ treated group
! 100
Mean No: live miracidia from vehicle treated group
Statistical analysis of miracidial survival was performed using
an unpaired Student’s t-test assuming unequal variance.
3. Results and discussion
In 2009, we (Melman et al., 2009) published a study measuring
PZQ sensitivity of S. mansoni miracidia hatched from eggs derived
from feces of adult Kenyan car washers and sand harvesters and
discovered there was a 2.42-fold increase in the chance that miracidia would survive PZQ exposure if they were from individuals
previously treated with PZQ compared to untreated. Miracidia
derived from patients who had had between 4 and 20 PZQ treatments showed mortality that ranged from 30 to over 80% when
exposed to 10"5 M PZQ in vitro, while the untreated cohort showed
mortality ranging from 60% to 100%. For this study we returned to
these occupational groups as well as a cohort of Kenyan school
children undergoing PZQ therapy to determine if there is significant variability in PZQ sensitivity of the S. mansoni population
infecting these individuals. In addition, we examined variation in
PZQ sensitivity of S. mansoni miracidia obtained from mice infected
with cercariae derived from naturally infected snail populations.
Fecal samples were obtained from a total of 72 individuals with
a history of treatment with PZQ. For the purpose of a direct control,
it was not possible to identify individuals within our patient
groups who had not received PZQ previously. Irrespective of the
patient group the mean miracidial mortality of S. mansoni at
10"5 M PZQ was between 82.1% and 84.6% with the lowest
observed value of miracidia from a single patient being 72.7%
(Table 1). As these data are comparable with the sensitivity of
miracidia derived from eggs of the untreated cohort in our 2009
study, it suggests there is no evidence of diminished PZQ sensitivity in S. mansoni infecting these populations. For the car washers
and sand harvesters, the last treatment dates were between 1
and 9 years before the current study and thus, it is perhaps not surprising that, without sustained PZQ treatment, a population of S.
mansoni with reduced responsiveness to PZQ has failed to materialize. In addition, there was no indication of reduced miracidial
susceptibility to PZQ among samples obtained from the 34 school
children that previously had between one and five PZQ treatments

Table 1
In vitro susceptibility to PZQ of S. mansoni miracidia derived from eggs in patient fecal samples.
Patient group and location

Car washers
Kisumu
Sand harvesters
Kisumu
School children
Mwea–MbuiNjera
School
children Mwea–Mukou
School children
Mwea–Thiba

No. of patients
sampled

Mean No. of PZQ treatments
per patient (range)

Mean% miracidial mortality (range)
10"6 M PZQ

10"5 M PZQ

14

8.4
(3–20)
4.7
(1–11)
3.8
(1–5)
3.3
(1–5)
3.8
(2–5)

26.1 ± 5.5
(17.7–33.3)
21.4 ± 3.1
(17.2–25.3)
27.4 ± 5.0
(19.4–32.1)
27.0 ± 5.4
(19.4–39.8)
25.4 ± 4.7
(21.0–32.5)

83.2 ± 4.2
(74.4–88.0)
81.5 ± 4.8
(72.7–88.8)
84.6 ± 4.8
(76.3–91.6)
83.8 ± 4.5
(76.5–90.7)
82.1 ± 3.7
(78.0 ± 82.6)

24
11
18
5

Data shown as mean ± 1 standard deviation.
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Table 2
Worms recovered from infected mice after treatment with PZQ during 5 passages of S.
mansoni.
Passage No.

PZQ treatment
mg/kg

No. of worms
Mean ± SD

Male:female
ratio

1

2 ! Vehicle
2 ! 100

48.0 ± 5.9*
37.2 ± 5.2

1.8
3.0

2

2 ! Vehicle
2 ! 100

43.8 ± 7.7
41.0 ± 7.6

2.6
3.1

3

2 ! Vehicle
2 ! 200

43.2 ± 4.6
36.4 ± 8.6

1.5
1.4

53.4 ± 4.2
49.6 ± 4.6

1.5
1.5

51.4 ± 1.7
50.2 ± 7.8

1.3
1.6

4
5

2 ! Vehicle
2 ! 250

2 ! Vehicle
3 ! 300

SD: 1 standard deviation.
*
p < 0.05.

(one treatment per year) as part of the Kenyan National Deworming Program. Similarly, when miracidia derived from mice
infected with cercariae from naturally infected snails collected in
Kisumu, Mwea and Kibwezi areas were tested, no evidence of
reduced susceptibility to PZQ was found (mortality at 10"5 M
PZQ = 82.3 ± 4.9%; range = 75.8–90.3%). Thus, using miracidia as
an indicator of S. mansoni sensitivity to PZQ in the definitive host
our data implies there is, as yet, no evidence to suggest that resistance or even reduced sensitivity is an immediate threat in the
areas surveyed.
Administration of one round of PZQ treatment to school children in Tanzania resulted in a significant reduction in genetic
diversity of S. mansoni populations within the children (Norton
et al., 2010; French et al., 2013). While there are many reasons to
account for such genetic ‘bottlenecking’ after PZQ treatment, one
concern is it may lead to a greater likelihood of development of
PZQ resistant parasite strains. Clearly, at least in the case of S. mansoni infecting the school children who took part in this study this
has not happened. A recent analysis of genetic variability of S. mansoni in this cohort suggests there has been no reduction in schistosome burden and genetic diversity actually increased after 4 years
of mass drug administration (data not shown). This latter observation would be more in agreement with Huyse et al. (2013) who
reported that regular treatment with PZQ did not affect the genetic
diversity of S. mansoni in Senegal.
In recent years, PZQ treatment of car washers and sand harvesters in Kisumu has become intermittent with the result that only a
small proportion of the infected population is undergoing treatment at any one time. This would leave a significant reservoir of
parasites unaffected by the drug and likely allow any S. mansoni
strain with reduced susceptibility to be lost from patients, especially if, as has been reported, an ability to withstand PZQ treatment also carries a cost to reproductive fitness (William et al.,
2001; Coeli et al., 2013). In order to determine if this population
still harbored the potential to generate S. mansoni with reduced
PZQ sensitivity, we used a mouse infection model to study the
impact of increasing amounts of PZQ on a population of parasites
derived from 7 car washers. During the first and second passages,
mice were treated with 100 mg/kg PZQ on days 28 and 35 after
infection. After the first passage there was a small but significant
fall in the number of worms recovered after treatment with
100 mg/kg PZQ compared to vehicle treated controls and an
increase in the male to female ratio from 1.8 to 3.0 (Table 2). During passage 5, 3 ! 300 mg/kg PZQ was administered to mice on
days 28, 35 and 37 after infection with no effect on worm numbers
or sex ratio compared with vehicle treated controls. In contrast,
treatment of mice infected with non-PZQ selected S. mansoni
during passages 3, 4 and 5 with 2 ! 200, 2 ! 250 and
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3 ! 300 mg/kg PZQ respectively resulted in 36, 66 and 86% reductions in worm numbers compared to vehicle treated mice. This
data suggests that we were able to generate a PZQ isolate with
low susceptibility to a normally effective dose of PZQ and is in
close accordance with that of Fallon and Doenhoff (1994) who used
a number of laboratory strains of S. mansoni from geographically
diverse regions as the source of their genetic material. Sexually
mature female worms isolated from bisexual infections in mice
have been shown to be less sensitive to PZQ in vitro than mature
male worms
(Pica-Mattoccia et al., 2004) while Delgado et al. (1992) showed a
preferential killing of female worms in vivo. Despite some initial
selection for males in the first round of PZQ treatment in the experiment reported here we saw no subsequent evidence for the selection of either sex. Interestingly, in a similar experiment using S.
mansoni LE strain, Coeli et al. (2013) were also able to generate
an isolate that was able to withstand 3 ! 300 mg/kg PZQ after 6
generations, but were unable to maintain the strain beyond the
11th generation under PZQ pressure due to a change in the male:
female ratio from 2.5 in treated, non-selected worms to 8.7 in treated, PZQ selected worms suggesting that female worms of the LE
strain are more susceptible to PZQ after repeated exposure and
selection. We will continue to passage our selected S. mansoni
strain to determine if heightened female sensitivity to PZQ
reported by Coeli et al. (2013) is due to the use of a laboratory
strain as the founder population or whether a more genetically
diverse founder population leads to a more stable long-term sex
ratio.
Miracidia hatched from livers of PZQ and vehicle treated mice
during each passage were assayed for their ability to survive PZQ
treatment in vitro (Fig. 1). Our data suggests that miracidia produced by drug-selected S. mansoni are also less susceptible to the
drug, especially during the 4th and 5th passage suggesting that
acquired resistance may be a heritable trait.
We have shown that a cohort of 72 adults and children living in
endemic areas of western and central Kenya who have undergone
recent or historical treatment with PZQ do not harbor S. mansoni
with reduced PZQ susceptibility. Nonetheless, while schistosomes
with a ‘resistant’ phenotype may not be problematic within these
populations, we have also shown there is a significant potential
for the emergence of such a phenotype should sufficient PZQ pressure be applied. It is fortuitous that with perhaps only approximately 15% of people with schistosomiasis being treated with
PZQ together with the intermittent nature of much of that treatment, a large refugium for drug sensitive parasites will continue
to exist. This, together with apparent fitness costs associated with
PZQ resistance (William et al., 2001; Coeli et al., 2013), may well
prevent the near-term establishment of drug resistant strains in
the human population. The far-term prospects for keeping resistance at bay are more worrisome. In 2012, the WHO announced
a ‘roadmap’ for the elimination of 17 neglected tropical diseases
(NTD) (World Health Organization, 2012), one of which was schistosomiasis. It was proposed that the disease could be eliminated as
a public health problem in multiple African countries by 2020 and
globally by 2025. This in turn inspired a global alliance of 22 partners including the WHO, The Bill and Melinda Gates Foundation,
World Bank and major pharmaceutical companies to announce
through the 2012 ‘London Declaration’ a sustained program to
‘control’ schistosomiasis by 2020 (http://unitingtocombatntds.
org). While 42 million PZQ tablets were dispensed in 2012
(World Health Organization, 2014) this number is likely to increase
greatly in the near future to meet the immediate goal of disease
control. Merck KgaA will make 250 million PZQ tablets per year
freely available in the medium-term and, with other manufacturers expected to contribute tablets to help bridge the expected
shortfall in supply, there are significant grounds for concern that
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Fig. 1. In vitro efficacy of 10"5 M PZQ in killing PZQ selected and non-selected S. mansoni miracidia. Mice infected with S. mansoni were treated with the indicated doses of
PZQ over 5 passages (selected) or PZQ vehicle alone (non-selected). The survival of the selected (j) and non-selected (}) miracidia treated with 10"5 M PZQ was calculated as
a percentage of vehicle treated controls at each time point. Data shown as mean + 1 SD (⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001).

drug pressure will increase significantly in the years ahead. Clearly,
close monitoring of drug efficacy should have an important role to
play as control efforts are ramped up in the coming years.
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